diastereoisomeric mixture - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	diastereoisomeric mixture	go back to main search page
Accession:	CHEBI:60915	browse the term
Definition:	A mixture composed of two or more diastereoisomers (stereoisomers not related as mirror images).
Synonyms:	related_synonym:	diastereomeric mixture

show annotations for term's descendants Sort by:
Rat (719) Mouse (754) Human (723) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (1) Green Monkey (0) Naked Mole-rat (0) All
Genes (719)

bitertanol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions
decreases activity

[prothioconazole co-treated with terbutylazine co-treated with bitertanol co-treated with cypermethrin co-treated with Malathion] results in increased activity of AHR protein; bitertanol inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]
bitertanol results in decreased activity of AHR protein

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

androgen receptor

multiple interactions

[bitertanol co-treated with propiconazole co-treated with cypermethrin] inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; [terbutylazine co-treated with bitertanol co-treated with propiconazole co-treated with cypermethrin co-treated with Malathion] inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; [terbutylazine co-treated with bitertanol co-treated with propiconazole co-treated with cypermethrin co-treated with Malathion] results in decreased activity of AR protein; bitertanol inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; bitertanol inhibits the reaction [Metribolone binds to and results in increased activity of AR protein]; Dihydrotestosterone inhibits the reaction [bitertanol results in increased activity of AR protein]

PMID:15064155 PMID:23871939

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions

[bitertanol co-treated with propiconazole co-treated with cypermethrin co-treated with Malathion co-treated with terbutylazine] results in increased expression of CYP19A1 mRNA

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

bitertanol results in increased expression of CYP1A1 mRNA; bitertanol results in increased expression of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 2, subfamily b, polypeptide 1

increases expression

bitertanol results in increased expression of CYP2B1 protein

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 2

increases expression

bitertanol results in increased expression of CYP2B2 protein

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases expression

bitertanol results in increased expression of CYP3A23-3A1 mRNA

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 51

decreases activity

bitertanol results in decreased activity of CYP51A1 protein

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410

G

hexosaminidase subunit beta

multiple interactions

zinc chloride inhibits the reaction [bitertanol results in increased secretion of HEXB protein]

NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223

G

matrix metallopeptidase 9

affects binding

bitertanol binds to MMP9 protein

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

bitertanol binds to and results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

cyproconazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminoadipate-semialdehyde synthase

decreases expression

cyproconazole results in decreased expression of AASS mRNA

NCBI chr 4:51,606,461...51,663,136
Ensembl chr 4:51,606,462...51,663,136

G

ATP binding cassette subfamily B member 11

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCB11 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of ABCB11 mRNA

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

increases expression
multiple interactions

cyproconazole results in increased expression of ABCB1A mRNA; cyproconazole results in increased expression of ABCB1A protein
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCB1A mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of ABCB1A mRNA

PMID:25182419 PMID:29038839 PMID:33150952

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

increases expression

cyproconazole results in increased expression of ABCB1B mRNA

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily C member 2

increases expression
multiple interactions

cyproconazole results in increased expression of ABCC2 mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCC2 mRNA

PMID:28058446 PMID:29038839

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

increases expression
multiple interactions

cyproconazole results in increased expression of ABCC3 mRNA; cyproconazole results in increased expression of ABCC3 protein
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCC3 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of ABCC3 mRNA
[NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of ABCC3 mRNA]; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of ABCC3 protein]

PMID:22334560 PMID:28058446 PMID:29038839 PMID:33150952

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 4

increases expression

cyproconazole results in increased expression of ABCC4 mRNA

PMID:22334560 PMID:23970803

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

abhydrolase domain containing 4, N-acyl phospholipase B

increases expression

cyproconazole results in increased expression of ABHD4 mRNA

NCBI chr15:27,697,384...27,716,013
Ensembl chr15:27,704,113...27,716,966

G

ABL proto-oncogene 1, non-receptor tyrosine kinase

multiple interactions

[cyproconazole co-treated with epoxiconazole] results in increased expression of ABL1 mRNA

NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065

G

acetyl-CoA acyltransferase 2

decreases expression

cyproconazole results in decreased expression of ACAA2 mRNA

NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249

G

acetyl-CoA acetyltransferase 1

decreases expression

cyproconazole results in decreased expression of ACAT1 mRNA

NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855

G

acetyl-CoA acetyltransferase 2

multiple interactions

[cyproconazole co-treated with epoxiconazole] results in increased expression of ACAT2 mRNA

NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821

G

ATP citrate lyase

increases expression

cyproconazole results in increased expression of ACLY mRNA

NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320

G

aconitase 1

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ACO1 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of ACO1 mRNA

NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391

G

acyl-CoA thioesterase 3

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ACOT3 mRNA

NCBI chr 6:103,682,518...103,688,735
Ensembl chr 6:103,682,596...103,688,427
Ensembl chr 6:103,682,596...103,688,427

G

acyl-CoA thioesterase 9

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ACOT9 mRNA

NCBI chr X:40,073,197...40,123,573
Ensembl chr X:40,064,810...40,123,559

G

acyl-CoA oxidase 1

decreases expression

cyproconazole results in decreased expression of ACOX1 protein

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

acid phosphatase 2, lysosomal

increases expression

cyproconazole results in increased expression of ACP2 mRNA

NCBI chr 3:77,175,022...77,185,180
Ensembl chr 3:77,175,895...77,185,680

G

acyl-CoA synthetase long-chain family member 1

decreases expression

cyproconazole results in decreased expression of ACSL1 mRNA

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

actinin, alpha 1

decreases expression

cyproconazole results in decreased expression of ACTN1 mRNA

NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251

G

ADAM metallopeptidase domain 11

increases expression

cyproconazole results in increased expression of ADAM11 mRNA

NCBI chr10:87,724,115...87,742,773
Ensembl chr10:87,724,234...87,741,562

G

adenylosuccinate synthase 1

increases expression

cyproconazole results in increased expression of ADSS1 mRNA

NCBI chr 6:131,679,795...131,702,012
Ensembl chr 6:131,679,701...131,701,998

G

AT hook containing transcription factor 1

decreases expression

cyproconazole results in decreased expression of AHCTF1 mRNA

NCBI chr13:91,481,936...91,536,391
Ensembl chr13:91,481,936...91,536,391

G

aryl hydrocarbon receptor

increases expression
multiple interactions

cyproconazole results in increased expression of AHR mRNA
[NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of AHR mRNA]

PMID:22334560 PMID:25182419 PMID:28058446 PMID:29038839

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

alpha-2-HS-glycoprotein

decreases expression

cyproconazole results in decreased expression of AHSG mRNA

NCBI chr11:78,121,388...78,127,998
Ensembl chr11:78,117,918...78,145,999

G

A-kinase anchoring protein 1

decreases expression

cyproconazole results in decreased expression of AKAP1 mRNA

NCBI chr10:73,621,021...73,654,123
Ensembl chr10:73,621,883...73,653,896

G

A-kinase anchoring protein 13

decreases expression

cyproconazole results in decreased expression of AKAP13 mRNA

NCBI chr 1:129,313,183...129,619,647
Ensembl chr 1:129,314,402...129,619,646

G

A-kinase anchoring protein 9

decreases expression

cyproconazole results in decreased expression of AKAP9 mRNA

NCBI chr 4:30,056,738...30,192,716
Ensembl chr 4:30,056,738...30,192,606

G

aldo-keto reductase family 1, member B7

increases expression

cyproconazole results in increased expression of AKR1B7 mRNA

PMID:22334560 PMID:23970803

NCBI chr 4:63,053,560...63,100,934
Ensembl chr 4:63,076,800...63,089,502

G

aldehyde dehydrogenase 1 family, member A1

increases expression
decreases expression
multiple interactions

cyproconazole results in increased expression of ALDH1A1 mRNA
cyproconazole results in decreased expression of ALDH1A1 protein
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ALDH1A1 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of ALDH1A1 mRNA

PMID:25182419 PMID:29038839 PMID:29995386

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

alsin Rho guanine nucleotide exchange factor ALS2

decreases expression

cyproconazole results in decreased expression of ALS2 mRNA

NCBI chr 9:60,613,182...60,686,394
Ensembl chr 9:60,613,167...60,670,737

G

annexin A7

increases expression

cyproconazole results in increased expression of ANXA7 mRNA

NCBI chr15:3,821,798...3,849,659
Ensembl chr15:3,821,845...3,849,385

G

apurinic/apyrimidinic endodeoxyribonuclease 1

increases expression
multiple interactions

cyproconazole results in increased expression of APEX1 mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of APEX1 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of APEX1 mRNA

NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785

G

apolipoprotein F

multiple interactions

[cyproconazole co-treated with epoxiconazole] results in increased expression of APOF mRNA

NCBI chr 7:700,688...702,130
Ensembl chr 7:700,762...701,946

G

arginase 1

increases expression

cyproconazole results in increased expression of ARG1 mRNA

NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422

G

Rho guanine nucleotide exchange factor 28

increases expression

cyproconazole results in increased expression of ARHGEF28 mRNA

NCBI chr 2:29,263,888...29,560,595
Ensembl chr 2:29,263,886...29,560,672

G

ADP-ribosylation factor like GTPase 5A

decreases expression

cyproconazole results in decreased expression of ARL5A mRNA

NCBI chr 3:36,878,461...36,903,362
Ensembl chr 3:36,880,712...36,903,211

G

cAMP-regulated phosphoprotein 19

increases expression

cyproconazole results in increased expression of ARPP19 mRNA

NCBI chr 8:75,779,640...75,802,474
Ensembl chr 8:75,779,523...75,802,452
Ensembl chr 8:75,779,523...75,802,452

G

N-acylsphingosine amidohydrolase 1

increases expression

cyproconazole results in increased expression of ASAH1 mRNA

NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233

G

asparagine synthetase (glutamine-hydrolyzing)

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ASNS mRNA

NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423

G

activating transcription factor 5

decreases expression

cyproconazole results in decreased expression of ATF5 mRNA

NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707

G

activating transcription factor 6

multiple interactions

[cyproconazole co-treated with epoxiconazole] results in increased expression of ATF6 mRNA

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

autophagy related 16-like 2

increases expression

cyproconazole results in increased expression of ATG16L2 mRNA

NCBI chr 1:155,687,386...155,703,419
Ensembl chr 1:155,684,564...155,703,420

G

ATM serine/threonine kinase

multiple interactions

[cyproconazole co-treated with epoxiconazole] results in increased expression of ATM mRNA

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase H+ transporting V0 subunit e1

increases expression

cyproconazole results in increased expression of ATP6V0E mRNA

NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434

G

ATPase phospholipid transporting 8B1

increases expression
multiple interactions

cyproconazole results in increased expression of ATP8B1 mRNA
[cyproconazole co-treated with epoxiconazole] results in increased expression of ATP8B1 mRNA

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

ataxin 7-like 3B

decreases expression

cyproconazole results in decreased expression of ATXN7L3B mRNA

NCBI chr 7:48,322,451...48,325,975
Ensembl chr 7:48,321,755...48,328,878

G

BCAR1 scaffold protein, Cas family member

decreases expression

cyproconazole results in decreased expression of BCAR1 mRNA

NCBI chr19:39,679,215...39,713,907
Ensembl chr19:39,679,204...39,713,907

G

betaine-homocysteine S-methyltransferase 2

decreases expression

cyproconazole results in decreased expression of BHMT2 mRNA

NCBI chr 2:24,895,525...24,912,475
Ensembl chr 2:24,895,533...24,912,475

G

BH3 interacting domain death agonist

decreases expression

cyproconazole results in decreased expression of BID mRNA

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

C2 calcium-dependent domain containing 2

decreases expression

cyproconazole results in decreased expression of C2CD2 mRNA

NCBI chr11:37,225,321...37,289,741
Ensembl chr11:37,227,415...37,289,739

G

complement C4B

decreases expression

cyproconazole results in decreased expression of C4B mRNA

NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681

G

calpain, small subunit 1

increases expression

cyproconazole results in increased expression of CAPNS1 mRNA

NCBI chr 1:85,444,613...85,454,861
Ensembl chr 1:85,444,608...85,454,795

G

cysteinyl-tRNA synthetase 1

decreases expression

cyproconazole results in decreased expression of CARS1 mRNA

NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941

G

caspase 7

multiple interactions

[cyproconazole co-treated with epoxiconazole] results in increased expression of CASP7 mRNA

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caveolin 1

decreases expression

cyproconazole results in decreased expression of CAV1 mRNA

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

CD24 molecule

affects expression

cyproconazole affects the expression of CD24A mRNA

NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662

G

CD36 molecule

increases expression
multiple interactions

cyproconazole results in increased expression of CD36 mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CD36 mRNA
[NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of CD36 mRNA]

PMID:22334560 PMID:28058446 PMID:29038839

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cell division cycle 34, ubiqiutin conjugating enzyme

increases expression

cyproconazole results in increased expression of CDC34 mRNA

NCBI chr 7:10,017,588...10,023,586
Ensembl chr 7:10,017,588...10,023,186

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

[NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of CDKN1A mRNA]
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in decreased expression of CDKN1A mRNA; [cyproconazole co-treated with epoxiconazole] results in decreased expression of CDKN1A mRNA

PMID:28058446 PMID:29038839

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

CDP-diacylglycerol synthase 2

increases expression

cyproconazole results in increased expression of CDS2 mRNA

NCBI chr 3:119,514,963...119,553,555
Ensembl chr 3:119,515,000...119,553,541

G

CCAAT/enhancer binding protein zeta

decreases expression

cyproconazole results in decreased expression of CEBPZ mRNA

NCBI chr 6:16,119,871...16,137,600
Ensembl chr 6:16,119,872...16,137,600

G

carboxylesterase 2C

increases expression
multiple interactions

cyproconazole results in increased expression of CES2C mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CES2C mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of CES2C mRNA

PMID:25182419 PMID:29038839

NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790

G

carboxylesterase 2H

increases expression

cyproconazole results in increased expression of CES2 mRNA
cyproconazole results in increased expression of CES2 protein

PMID:22334560 PMID:29995386

NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830

G

CGG triplet repeat binding protein 1

decreases expression

cyproconazole results in decreased expression of CGGBP1 mRNA

NCBI chr11:2,565,629...2,572,869
Ensembl chr11:2,565,484...2,573,031

G

chromodomain helicase DNA binding protein 1-like

increases expression

cyproconazole results in increased expression of CHD1L mRNA

NCBI chr 2:185,138,526...185,217,498
Ensembl chr 2:185,139,308...185,217,595

G

choline kinase alpha

decreases expression

cyproconazole results in decreased expression of CHKA mRNA

NCBI chr 1:201,076,804...201,125,517
Ensembl chr 1:201,076,860...201,125,516

G

cytidine monophospho-N-acetylneuraminic acid hydroxylase

decreases expression

cyproconazole results in decreased expression of CMAH mRNA

NCBI chr17:40,557,161...40,642,350
Ensembl chr17:40,583,667...40,642,275

G

catechol-O-methyltransferase

multiple interactions

[cyproconazole co-treated with epoxiconazole] results in increased expression of COMT mRNA

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

carnitine palmitoyltransferase 2

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CPT2 mRNA

NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095

G

cellular repressor of E1A-stimulated genes 1

increases expression

cyproconazole results in increased expression of CREG1 mRNA

NCBI chr13:78,019,814...78,032,310
Ensembl chr13:78,019,843...78,032,308

G

C-reactive protein

increases expression

cyproconazole results in increased expression of CRP mRNA

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

cathepsin D

increases expression

cyproconazole results in increased expression of CTSD mRNA

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cathepsin E

multiple interactions

[cyproconazole co-treated with epoxiconazole] results in increased expression of CTSE mRNA

NCBI chr13:43,091,954...43,114,509
Ensembl chr13:43,092,128...43,114,502

G

cathepsin L

increases expression

cyproconazole results in increased expression of CTSL mRNA

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cathepsin O

increases expression

cyproconazole results in increased expression of CTSO mRNA

NCBI chr 2:167,230,407...167,254,761
Ensembl chr 2:167,230,330...167,253,702

G

C-X-C motif chemokine ligand 12

affects expression

cyproconazole affects the expression of CXCL12 mRNA

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

cytochrome b5 type A

increases expression

cyproconazole results in increased expression of CYB5A mRNA

NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535
Ensembl chr18:78,202,342...78,258,535

G

cytochrome P450, family 11, subfamily b, polypeptide 2

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in decreased expression of CYP11B1 mRNA

NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004

G

cytochrome P450, family 11, subfamily b, polypeptide 3

decreases expression

cyproconazole results in decreased expression of CYP11B2 mRNA

NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions

[prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased expression of CYP19A1 mRNA

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression
multiple interactions

cyproconazole results in increased expression of CYP1A1 mRNA
[cyproconazole co-treated with azoxystrobin] results in increased expression of CYP1A1 mRNA
[epoxiconazole co-treated with cyproconazole] results in increased activity of CYP1A1 protein; [epoxiconazole co-treated with cyproconazole] results in increased expression of CYP1A1 mRNA; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased activity of CYP1A1 protein; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased expression of CYP1A1 mRNA
cyproconazole results in increased expression of CYP1A1 mRNA; cyproconazole results in increased expression of CYP1A1 protein

PMID:25182419 PMID:29038839 PMID:29294346 PMID:32194361 PMID:33150952

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression
multiple interactions

cyproconazole results in increased expression of CYP1A2 mRNA
cyproconazole results in increased expression of CYP1A2 protein
cyproconazole results in increased expression of CYP1A2 mRNA; cyproconazole results in increased expression of CYP1A2 protein
NR1I3 promotes the reaction [cyproconazole results in increased expression of CYP1A2 mRNA]

PMID:22334560 PMID:25656644 PMID:29995386 PMID:33150952

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 26, subfamily a, polypeptide 1

increases expression

cyproconazole results in increased expression of CYP26A1 mRNA

NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204

G

cytochrome P450, family 26, subfamily b, polypeptide 1

increases expression

cyproconazole results in increased expression of CYP26B1 mRNA

NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628

G

cytochrome P450, family 2, subfamily b, polypeptide 1

increases expression
multiple interactions
increases activity

cyproconazole results in increased expression of CYP2B1 mRNA
[cyproconazole co-treated with epoxiconazole] results in increased expression of CYP2B1 mRNA; [epoxiconazole co-treated with cyproconazole] results in increased activity of CYP2B1 protein; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased activity of CYP2B1 protein; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased expression of CYP2B1 mRNA
cyproconazole results in increased activity of CYP2B1 protein

PMID:25182419 PMID:29038839

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 15

increases expression

cyproconazole results in increased expression of CYP2B15 mRNA

NCBI chr 1:82,094,188...82,106,492
Ensembl chr 1:82,094,180...82,106,492

G

cytochrome P450, family 2, subfamily b, polypeptide 2

multiple interactions
increases expression

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CYP2B2 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of CYP2B2 mRNA
cyproconazole results in increased expression of CYP2B2 mRNA

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions
increases expression

[cyproconazole co-treated with azoxystrobin] results in increased expression of CYP2B6 protein; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of CYP2B10 protein]; [NR1I3 protein co-treated with NR1I2 protein] affects the reaction [cyproconazole results in increased expression of CYP2B10 mRNA]
NR1I3 promotes the reaction [cyproconazole results in increased expression of CYP2B10 mRNA]; NR1I3 protein mutant form inhibits the reaction [cyproconazole results in increased expression of CYP2B10 mRNA]; NR1I3 protein mutant form inhibits the reaction [cyproconazole results in increased expression of CYP2B10 protein]
cyproconazole results in increased expression of CYP2B10 mRNA; cyproconazole results in increased expression of CYP2B10 protein
cyproconazole results in increased expression of CYP2B6 mRNA; cyproconazole results in increased expression of CYP2B6 protein

PMID:17557908 PMID:22334560 PMID:23970803 PMID:25656644 PMID:28058446 More...

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily c, polypeptide 13

increases expression

cyproconazole results in increased expression of CYP2C13 protein

NCBI chr 1:238,786,764...238,867,195
Ensembl chr 1:238,786,765...238,867,191

G

cytochrome P450, family 2, subfamily c, polypeptide 24

increases expression

cyproconazole results in increased expression of CYP2C55 mRNA; cyproconazole results in increased expression of CYP2C55 protein

PMID:22334560 PMID:23970803 PMID:33150952

NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases expression

cyproconazole results in increased expression of CYP2C6 mRNA
cyproconazole results in increased expression of CYP2C29 protein
cyproconazole results in increased expression of CYP2C19 protein

PMID:25182419 PMID:32194361 PMID:33150952

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions
increases expression
decreases expression

[cyproconazole co-treated with epoxiconazole] results in increased expression of CYP2E1 mRNA
cyproconazole results in increased expression of CYP2E1 protein
cyproconazole results in decreased expression of CYP2E1 protein
cyproconazole results in decreased expression of CYP2E1 mRNA

PMID:29038839 PMID:29995386 PMID:33150952

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 18

increases expression

cyproconazole results in increased expression of CYP3A18 protein

NCBI chr12:8,880,509...8,930,382
Ensembl chr12:8,880,528...8,930,381

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases expression

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CYP3A2 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of CYP3A2 mRNA
[Amiodarone co-treated with Benzoic Acid co-treated with cyproconazole co-treated with flusilazole co-treated with enilconazole co-treated with prochloraz co-treated with propiconazole co-treated with tebuconazole] results in increased expression of CYP3A4 protein; [azoxystrobin co-treated with cyproconazole] results in increased expression of CYP3A4 protein; [cyproconazole co-treated with azoxystrobin] results in increased expression of CYP3A4 mRNA
cyproconazole results in increased expression of CYP3A4 mRNA; cyproconazole results in increased expression of CYP3A4 protein

PMID:29038839 PMID:29294346 PMID:29995386 PMID:33150952 PMID:34273450

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases expression
multiple interactions
increases activity

cyproconazole results in increased expression of CYP3A23-3A1 mRNA
[cyproconazole co-treated with epoxiconazole] results in increased expression of CYP3A23-3A1 mRNA; [epoxiconazole co-treated with cyproconazole] results in increased activity of CYP3A23-3A1 protein; [prochloraz co-treated with cyproconazole co-treated with epoxiconazole] results in increased expression of CYP3A23-3A1 mRNA; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased activity of CYP3A23-3A1 protein
cyproconazole results in increased activity of CYP3A23-3A1 protein

PMID:25182419 PMID:29038839

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression

cyproconazole results in increased expression of CYP3A9 protein

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450, family 51

affects expression
decreases activity

cyproconazole affects the expression of CYP51 mRNA
cyproconazole results in decreased activity of CYP51A1 protein

PMID:16989930 PMID:22045034

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions
decreases expression

[cyproconazole co-treated with epoxiconazole] results in increased expression of CYP7A1 mRNA
cyproconazole results in decreased expression of CYP7A1 mRNA

PMID:29038839 PMID:29995386

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

dihydrolipoamide branched chain transacylase E2

decreases expression

cyproconazole results in decreased expression of DBT mRNA

NCBI chr 2:204,481,744...204,510,612
Ensembl chr 2:204,481,737...204,510,609

G

dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit

increases expression

cyproconazole results in increased expression of DDOST mRNA

NCBI chr 5:150,522,297...150,529,413
Ensembl chr 5:150,522,242...150,529,413

G

DEAD-box helicase 46

decreases expression

cyproconazole results in decreased expression of DDX46 mRNA

NCBI chr17:8,942,070...8,988,440
Ensembl chr17:8,944,454...8,988,439

G

DEAD-box helicase 6

decreases expression

cyproconazole results in decreased expression of DDX6 mRNA

PMID:22334560 PMID:23970803

NCBI chr 8:44,931,127...44,967,773
Ensembl chr 8:44,931,974...44,964,405

G

Dexi homolog

decreases expression

cyproconazole results in decreased expression of DEXI mRNA

NCBI chr10:5,126,021...5,138,746
Ensembl chr10:5,137,288...5,138,738

G

dehydrogenase/reductase 3

increases expression

cyproconazole results in increased expression of DHRS3 mRNA

NCBI chr 5:156,747,939...156,782,420
Ensembl chr 5:156,747,962...156,782,417

G

diablo, IAP-binding mitochondrial protein

increases expression
multiple interactions

cyproconazole results in increased expression of DIABLO mRNA
[cyproconazole co-treated with epoxiconazole] results in increased expression of DIABLO mRNA

NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387

G

distal-less homeobox 5

decreases expression

cyproconazole results in decreased expression of DLX5 mRNA

NCBI chr 4:34,999,139...35,003,504
Ensembl chr 4:34,999,139...35,003,407

G

dimethylglycine dehydrogenase

decreases expression

cyproconazole results in decreased expression of DMGDH mRNA

NCBI chr 2:24,912,600...24,987,533
Ensembl chr 2:24,912,578...24,987,528

G

dynein, axonemal, intermediate chain 1

decreases expression

cyproconazole results in decreased expression of DNAI1 mRNA

PMID:22334560 PMID:23970803

NCBI chr 5:56,730,179...56,800,926
Ensembl chr 5:56,730,179...56,800,925

G

dolichyl-phosphate N-acetylglucosaminephosphotransferase 1

increases expression

cyproconazole results in increased expression of DPAGT1 mRNA

NCBI chr 8:44,664,055...44,671,102
Ensembl chr 8:44,664,071...44,671,087

G

dual specificity phosphatase 3

increases expression

cyproconazole results in increased expression of DUSP3 mRNA

NCBI chr10:86,920,014...86,933,739
Ensembl chr10:86,920,014...86,933,962

G

dual specificity phosphatase 5

increases expression

cyproconazole results in increased expression of DUSP5 mRNA

NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818

G

early growth response 2

decreases expression

cyproconazole results in decreased expression of EGR2 mRNA

NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of EHHADH mRNA

NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of EIF2AK3 mRNA

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 4, gamma 2

decreases expression

cyproconazole results in decreased expression of EIF4G2 mRNA

NCBI chr 1:165,181,433...165,193,583
Ensembl chr 1:165,181,434...165,193,588

G

ELOVL fatty acid elongase 1

increases expression

cyproconazole results in increased expression of ELOVL1 mRNA

NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958

G

energy homeostasis associated

decreases expression

cyproconazole results in decreased expression of ENHO mRNA

NCBI chr 5:56,800,980...56,802,777
Ensembl chr 5:56,800,980...56,802,777

G

ectonucleoside triphosphate diphosphohydrolase 5

increases expression

cyproconazole results in increased expression of ENTPD5 mRNA

NCBI chr 6:104,019,095...104,055,311
Ensembl chr 6:104,019,185...104,055,530

G

E1A binding protein p300

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of EP300 mRNA

NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

Eph receptor A2

decreases expression

cyproconazole results in decreased expression of EPHA2 mRNA

NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117

G

epoxide hydrolase 1

increases expression
multiple interactions

cyproconazole results in increased expression of EPHX1 mRNA
[cyproconazole co-treated with epoxiconazole] results in increased expression of EPHX1 mRNA

PMID:22334560 PMID:29038839

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

epoxide hydrolase 2

decreases expression

cyproconazole results in decreased expression of EPHX2 mRNA

NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615

G

ERCC excision repair 1, endonuclease non-catalytic subunit

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ERCC1 mRNA

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

estrogen-related receptor beta

decreases expression

cyproconazole results in decreased expression of ESRRB mRNA

NCBI chr 6:106,007,701...106,163,136
Ensembl chr 6:106,008,095...106,160,791

G

electron transfer flavoprotein subunit alpha

decreases expression

cyproconazole results in decreased expression of ETFA mRNA

NCBI chr 8:55,835,115...55,891,890
Ensembl chr 8:55,835,134...55,891,969

G

ethanolamine-phosphate phospho-lyase

decreases expression

cyproconazole results in decreased expression of ETNPPL mRNA

NCBI chr 2:219,173,048...219,194,646
Ensembl chr 2:219,172,978...219,192,212

G

ETS variant transcription factor 4

decreases expression

cyproconazole results in decreased expression of ETV4 mRNA

NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974

G

exosome component 8

increases expression

cyproconazole results in increased expression of EXOSC8 mRNA

NCBI chr 2:138,930,405...138,937,009
Ensembl chr 2:138,930,405...138,936,928

G

coagulation factor X

increases expression

cyproconazole results in increased expression of F10 mRNA

NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141

G

coagulation factor V

decreases expression

cyproconazole results in decreased expression of F5 mRNA

NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317

G

fumarylacetoacetate hydrolase

decreases expression

cyproconazole results in decreased expression of FAH mRNA

NCBI chr 1:138,548,830...138,571,599
Ensembl chr 1:138,548,834...138,571,505

G

family with sequence similarity 114, member A1

increases expression

cyproconazole results in increased expression of FAM114A1 mRNA

NCBI chr14:43,275,693...43,346,154
Ensembl chr14:43,275,701...43,346,174

G

family with sequence similarity 168, member A

decreases expression

cyproconazole results in decreased expression of FAM168A mRNA

NCBI chr 1:155,057,352...155,203,439
Ensembl chr 1:155,057,352...155,201,220

G

Fas cell surface death receptor

increases expression
multiple interactions

cyproconazole results in increased expression of FAS mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of FAS mRNA

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

fatty acid synthase

increases expression
decreases expression

cyproconazole results in increased expression of FASN mRNA
cyproconazole results in decreased expression of FASN mRNA; cyproconazole results in decreased expression of FASN protein

PMID:29038839 PMID:29995386

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fibrillin 2

increases expression

cyproconazole results in increased expression of FBN2 mRNA

NCBI chr18:51,499,670...51,703,976
Ensembl chr18:51,499,737...51,703,976

G

farnesyl diphosphate farnesyl transferase 1

affects expression

cyproconazole affects the expression of FDFT1 mRNA

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

farnesyl diphosphate synthase

affects expression

cyproconazole affects the expression of FDPS mRNA

NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776

G

fasciculation and elongation protein zeta 2

increases expression

cyproconazole results in increased expression of FEZ2 mRNA

NCBI chr 6:16,654,572...16,694,628
Ensembl chr 6:16,654,614...16,694,626

G

fibroblast growth factor 1

decreases expression

cyproconazole results in decreased expression of FGF1 mRNA

NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357

G

forkhead box A2

increases expression

cyproconazole results in increased expression of FOXA2 mRNA

NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326

G

forkhead box G1

increases expression

cyproconazole results in increased expression of FOXG1 mRNA

NCBI chr 6:66,674,797...66,677,611
Ensembl chr 6:66,666,587...66,678,607

G

G3BP stress granule assembly factor 2

increases expression

cyproconazole results in increased expression of G3BP2 mRNA

NCBI chr14:15,932,403...16,020,555
Ensembl chr14:15,987,417...16,020,548

G

glutamate decarboxylase 1

decreases expression

cyproconazole results in decreased expression of GAD1 mRNA

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

growth arrest and DNA-damage-inducible, alpha

increases expression

cyproconazole results in increased expression of GADD45 mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

growth arrest and DNA-damage-inducible, beta

multiple interactions
increases expression

NR1I3 protein mutant form inhibits the reaction [cyproconazole results in increased expression of GADD45B mRNA]

PMID:17557908 PMID:22334560 PMID:23970803 PMID:25656644

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

GTP cyclohydrolase 1

increases expression

cyproconazole results in increased expression of GCH1 mRNA

NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698

G

GDNF family receptor alpha 3

affects expression

cyproconazole affects the expression of GFRA3 mRNA

NCBI chr18:26,297,828...26,326,105
Ensembl chr18:26,297,829...26,326,105

G

growth hormone receptor

decreases expression

cyproconazole results in decreased expression of GHR mRNA

NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735

G

gap junction protein, beta 5

decreases expression

cyproconazole results in decreased expression of GJB5 mRNA

NCBI chr 5:139,680,670...139,683,588
Ensembl chr 5:139,680,671...139,683,583

G

GLI family zinc finger 2

affects expression

cyproconazole affects the expression of GLI2 mRNA

NCBI chr13:29,946,882...30,163,589
Ensembl chr13:29,946,809...30,163,574

G

glutaredoxin

increases expression

cyproconazole results in increased expression of GLRX mRNA

NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680

G

glutaredoxin 5

increases expression

cyproconazole results in increased expression of GLRX5 mRNA

NCBI chr 6:123,988,461...123,998,545
Ensembl chr 6:123,988,134...123,998,545

G

glutaminase 2

decreases expression

cyproconazole results in decreased expression of GLS2 mRNA

NCBI chr 7:617,252...633,424
Ensembl chr 7:617,288...633,426

G

glutamate dehydrogenase 1

decreases expression

cyproconazole results in decreased expression of GLUD1 mRNA

NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957

G

glycerol-3-phosphate dehydrogenase 1

decreases expression

cyproconazole results in decreased expression of GPD1 protein

NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529

G

glutathione peroxidase 2

decreases expression
multiple interactions
increases expression

cyproconazole results in decreased expression of GPX2 mRNA
[cyproconazole co-treated with epoxiconazole] results in increased expression of GPX2 mRNA
cyproconazole results in increased expression of GPX2 mRNA

PMID:25182419 PMID:29038839

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutathione peroxidase 4

increases expression

cyproconazole results in increased expression of GPX4 mRNA

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

granulin precursor

increases expression

cyproconazole results in increased expression of GRN mRNA

NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775

G

glutathione-disulfide reductase

increases expression

cyproconazole results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase alpha 2

increases expression

cyproconazole results in increased expression of GSTA2 mRNA

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

glutathione S-transferase alpha 5

increases expression
multiple interactions

cyproconazole results in increased expression of GSTA5 mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of GSTA5 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of GSTA5 mRNA

NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472

G

glutathione S-transferase mu 1

increases expression

cyproconazole results in increased expression of GSTM1 mRNA

PMID:22334560 PMID:25182419

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase mu 2

increases expression

cyproconazole results in increased expression of GSTM2 mRNA

PMID:22334560 PMID:25182419

NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961

G

glutathione S-transferase mu 4

increases expression

cyproconazole results in increased expression of GSTM4 mRNA

NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323

G

glutathione S-transferase, mu 5

increases expression

cyproconazole results in increased expression of GSTM3 mRNA

PMID:22334560 PMID:23970803

NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553

G

glutathione S-transferase theta 1

increases expression

cyproconazole results in increased expression of GSTT1 mRNA

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

3-hydroxyanthranilate 3,4-dioxygenase

decreases expression

cyproconazole results in decreased expression of HAAO mRNA
cyproconazole results in decreased expression of HAAO protein

PMID:22334560 PMID:29995386

NCBI chr 6:10,845,235...10,864,863
Ensembl chr 6:10,845,771...10,864,877

G

3-hydroxyacyl-CoA dehydratase 1

increases expression

cyproconazole results in increased expression of HACD1 mRNA

NCBI chr17:77,081,508...77,106,114
Ensembl chr17:77,083,740...77,106,073

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha

multiple interactions

[cyproconazole co-treated with epoxiconazole] results in increased expression of HADHA mRNA

NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869

G

histidine ammonia lyase

decreases expression

cyproconazole results in decreased expression of HAL mRNA

NCBI chr 7:28,007,449...28,037,701
Ensembl chr 7:28,006,972...28,037,701

G

hydroxyacid oxidase 1

decreases expression

cyproconazole results in decreased expression of HAO1 mRNA

NCBI chr 3:121,757,400...121,828,721
Ensembl chr 3:121,771,836...121,828,721

G

HECT domain E3 ubiquitin protein ligase 1

decreases expression
increases expression

cyproconazole results in decreased expression of HECTD1 mRNA
cyproconazole results in increased expression of HECTD1 mRNA

PMID:22045034 PMID:22334560

NCBI chr 6:69,181,429...69,268,045
Ensembl chr 6:69,181,436...69,268,053

G

HECT domain E3 ubiquitin protein ligase 2

decreases expression

cyproconazole results in decreased expression of HECTD2 mRNA

NCBI chr 1:234,274,967...234,345,598
Ensembl chr 1:234,275,705...234,343,487

G

homocysteine inducible ER protein with ubiquitin like domain 1

multiple interactions

[cyproconazole co-treated with epoxiconazole] results in increased expression of HERPUD1 mRNA

NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424

G

HIG1 hypoxia inducible domain family, member 1C

increases expression

cyproconazole results in increased expression of HIGD1C mRNA

NCBI chr 7:131,477,730...131,498,853
Ensembl chr 7:131,478,519...131,498,214

G

histone cluster 2 H2B family member E

decreases expression

cyproconazole results in decreased expression of H2BC21 mRNA

NCBI chr 2:183,780,583...183,783,030

G

3-hydroxy-3-methylglutaryl-CoA reductase

affects expression

cyproconazole affects the expression of HMGCR mRNA

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

high mobility group nucleosome binding domain 1

increases expression

cyproconazole results in increased expression of HMGN1 mRNA

NCBI chr11:35,422,328...35,428,247
Ensembl chr11:35,422,328...35,428,254

G

homeo box B4

increases expression

cyproconazole results in increased expression of HOXB4 mRNA

NCBI chr10:81,284,552...81,287,134
Ensembl chr10:81,284,552...81,287,128

G

homeo box B5

increases expression

cyproconazole results in increased expression of HOXB5 mRNA

NCBI chr10:81,269,372...81,271,580
Ensembl chr10:81,269,372...81,271,580

G

homeo box C4

increases expression

cyproconazole results in increased expression of HOXC4 mRNA

NCBI chr 7:134,135,279...134,173,133
Ensembl chr 7:134,170,591...134,173,133

G

hypoxanthine phosphoribosyltransferase 1

decreases expression
increases expression

cyproconazole results in decreased expression of HPRT1 mRNA
cyproconazole results in increased expression of HPRT1 mRNA

PMID:22045034 PMID:22334560

NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154

G

hydroxysteroid (17-beta) dehydrogenase 7

affects expression

cyproconazole affects the expression of HSD17B7 mRNA

NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017

G

heat shock protein family A (Hsp70) member 13

increases expression

cyproconazole results in increased expression of HSPA13 mRNA

NCBI chr11:14,375,669...14,389,853
Ensembl chr11:14,373,275...14,389,895

G

heat shock protein family B (small) member 8

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of HSPB8 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of HSPB8 mRNA

NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185

G

isopentenyl-diphosphate delta isomerase 1

increases expression

cyproconazole results in increased expression of IDI1 mRNA

NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357

G

interferon alpha and beta receptor subunit 2

increases expression

cyproconazole results in increased expression of IFNAR2 mRNA

NCBI chr11:30,613,576...30,645,958
Ensembl chr11:30,613,767...30,668,124

G

insulin-like growth factor 1

decreases expression

cyproconazole results in decreased expression of IGF1 mRNA

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor binding protein, acid labile subunit

decreases expression

cyproconazole results in decreased expression of IGFALS mRNA

NCBI chr10:13,897,468...13,903,920
Ensembl chr10:13,898,395...13,902,677

G

inhibitor of nuclear factor kappa B kinase subunit epsilon

increases expression

cyproconazole results in increased expression of IKBKE mRNA

NCBI chr13:42,712,154...42,738,470
Ensembl chr13:42,712,159...42,737,143

G

interleukin 1 receptor accessory protein

decreases expression

cyproconazole results in decreased expression of IL1RAP mRNA

NCBI chr11:74,062,999...74,199,530
Ensembl chr11:74,070,304...74,199,530

G

impact RWD domain protein

increases expression

cyproconazole results in increased expression of IMPACT mRNA

NCBI chr18:4,108,872...4,147,571
Ensembl chr18:4,108,853...4,147,569

G

inosine monophosphate dehydrogenase 2

decreases expression

cyproconazole results in decreased expression of IMPDH2 mRNA

NCBI chr 8:109,256,705...109,261,365
Ensembl chr 8:109,256,728...109,261,359

G

insulin induced gene 1

increases expression

cyproconazole results in increased expression of INSIG1 mRNA

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

interferon regulatory factor 6

increases expression

cyproconazole results in increased expression of IRF6 mRNA

NCBI chr13:104,672,179...104,691,386
Ensembl chr13:104,672,179...104,691,386

G

integrin subunit alpha 8

increases expression

cyproconazole results in increased expression of ITGA8 mRNA

NCBI chr17:75,304,004...75,501,510
Ensembl chr17:75,304,008...75,501,510

G

integrin subunit alpha X

multiple interactions

[cyproconazole co-treated with epoxiconazole] results in increased expression of ITGAX mRNA

NCBI chr 1:182,709,653...182,740,709
Ensembl chr 1:182,719,609...182,740,698

G

inter-alpha trypsin inhibitor, heavy chain 1

decreases expression

cyproconazole results in decreased expression of ITIH1 mRNA

NCBI chr16:6,122,246...6,136,363
Ensembl chr16:6,122,248...6,136,363

G

inter-alpha-trypsin inhibitor heavy chain 2

decreases expression

cyproconazole results in decreased expression of ITIH2 mRNA

NCBI chr17:68,375,574...68,411,849
Ensembl chr17:68,375,567...68,411,841

G

inter-alpha trypsin inhibitor, heavy chain 3

decreases expression

cyproconazole results in decreased expression of ITIH3 mRNA

NCBI chr16:6,101,922...6,117,154
Ensembl chr16:6,101,930...6,116,924

G

integral membrane protein 2C

increases expression

cyproconazole results in increased expression of ITM2C mRNA

NCBI chr 9:86,545,927...86,559,745
Ensembl chr 9:86,545,921...86,559,742

G

ketohexokinase

decreases expression

cyproconazole results in decreased expression of KHK protein

NCBI chr 6:25,445,298...25,455,834
Ensembl chr 6:25,445,300...25,455,717

G

lactate dehydrogenase A

decreases expression

cyproconazole results in decreased expression of LDHA mRNA

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

low density lipoprotein receptor

affects expression

cyproconazole affects the expression of LDLR mRNA

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

left right determination factor 1

increases expression

cyproconazole results in increased expression of LEFTY1 mRNA

NCBI chr13:92,649,226...92,659,722
Ensembl chr13:92,656,323...92,659,720

G

LON peptidase N-terminal domain and ring finger 3

decreases expression

cyproconazole results in decreased expression of LONRF3 mRNA

NCBI chr X:115,565,214...115,603,886
Ensembl chr X:115,565,267...115,598,809

G

lecithin retinol acyltransferase

decreases expression

cyproconazole results in decreased expression of LRAT mRNA

NCBI chr 2:168,264,093...168,273,155
Ensembl chr 2:168,266,877...168,273,619

G

leucine rich repeat containing 3

decreases expression

cyproconazole results in decreased expression of LRRC3 mRNA

NCBI chr20:10,758,919...10,763,736
Ensembl chr20:10,758,955...10,762,067

G

leucine rich repeat containing 75A

increases expression

cyproconazole results in increased expression of LRRC75A mRNA

NCBI chr10:47,298,222...47,343,301
Ensembl chr10:47,297,288...47,343,664

G

lanosterol synthase

multiple interactions

[cyproconazole co-treated with epoxiconazole] results in increased expression of LSS mRNA

NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762

G

LUC7-like 3 pre-mRNA splicing factor

decreases expression

cyproconazole results in decreased expression of LUC7L3 mRNA

NCBI chr10:79,240,050...79,276,555
Ensembl chr10:79,240,563...79,276,538

G

macrophage erythroblast attacher, E3 ubiquitin ligase

increases expression

cyproconazole results in increased expression of MAEA mRNA

NCBI chr14:77,357,261...77,390,683
Ensembl chr14:77,357,264...77,390,671

G

MAF bZIP transcription factor B

decreases expression

cyproconazole results in decreased expression of MAFB mRNA

NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031

G

magnesium transporter 1

increases expression

cyproconazole results in increased expression of MAGT1 mRNA

NCBI chr X:71,038,489...71,079,704
Ensembl chr X:71,038,489...71,079,699

G

mannosidase beta

multiple interactions
increases expression

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MANBA mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of MANBA mRNA
cyproconazole results in increased expression of MANBA mRNA

NCBI chr 2:223,910,432...224,002,988
Ensembl chr 2:223,910,432...224,002,983

G

microtubule-associated protein 2

increases expression

cyproconazole results in increased expression of MAP2 mRNA

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

mitogen activated protein kinase 3

decreases expression

cyproconazole results in decreased expression of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

muscleblind-like splicing regulator 2

increases expression

cyproconazole results in increased expression of MBNL2 mRNA

NCBI chr15:97,385,278...97,542,924
Ensembl chr15:97,385,244...97,542,937

G

MDM2 proto-oncogene

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MDM2 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of MDM2 mRNA

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

meiosis/spermiogenesis associated 1

increases expression

cyproconazole results in increased expression of MEIG1 mRNA

NCBI chr17:74,810,791...74,828,433
Ensembl chr17:74,814,632...74,828,433

G

mesoderm development LRP chaperone

increases expression

cyproconazole results in increased expression of MESD mRNA

NCBI chr 1:137,866,707...137,879,999
Ensembl chr 1:137,874,242...137,879,999

G

MET proto-oncogene, receptor tyrosine kinase

decreases expression

cyproconazole results in decreased expression of MET mRNA

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

major facilitator superfamily domain containing 11

increases expression

cyproconazole results in increased expression of MFSD11 mRNA

NCBI chr10:102,055,516...102,075,064
Ensembl chr10:102,056,051...102,075,064

G

marker of proliferation Ki-67

increases expression

cyproconazole results in increased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

malectin

increases expression

cyproconazole results in increased expression of MLEC mRNA

NCBI chr12:41,458,234...41,468,710
Ensembl chr12:41,458,231...41,468,708

G

MAX dimerization protein MLX

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MLX mRNA

NCBI chr10:86,019,216...86,024,326
Ensembl chr10:86,019,588...86,032,350

G

MORC family CW-type zinc finger 3

increases expression

cyproconazole results in increased expression of MORC3 mRNA

NCBI chr11:33,151,906...33,194,650
Ensembl chr11:33,152,025...33,194,646

G

mitochondrial ribosomal protein L54

increases expression

cyproconazole results in increased expression of MRPL54 mRNA

NCBI chr 7:8,452,801...8,455,321
Ensembl chr 7:8,452,716...8,455,321

G

mitochondrial ribosomal protein S18B

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MRPS18B mRNA

NCBI chr20:2,838,174...2,844,260
Ensembl chr20:2,838,030...2,844,260

G

methylsterol monooxygenase 1

affects expression
multiple interactions

cyproconazole affects the expression of MSMO1 mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MSMO1 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of MSMO1 mRNA

PMID:22045034 PMID:29038839

NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016

G

msh homeobox 1

decreases expression

cyproconazole results in decreased expression of MSX1 mRNA

NCBI chr14:72,961,036...72,964,970
Ensembl chr14:72,961,148...72,964,966

G

metallothionein 2A

increases expression

cyproconazole results in increased expression of MT2 mRNA

PMID:22334560 PMID:23970803

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

methylenetetrahydrofolate reductase

increases expression

cyproconazole results in increased expression of MTHFR mRNA

NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797

G

microsomal triglyceride transfer protein

decreases expression

cyproconazole results in decreased expression of MTTP protein

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

murinoglobulin 1

decreases expression

cyproconazole results in decreased expression of MUG1 mRNA

NCBI chr 4:155,076,270...155,130,051
Ensembl chr 4:155,076,312...155,130,051

G

mevalonate diphosphate decarboxylase

affects expression

cyproconazole affects the expression of MVD mRNA

NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971

G

mevalonate kinase

decreases expression

cyproconazole results in decreased expression of MVK mRNA

NCBI chr12:42,141,391...42,158,893
Ensembl chr12:42,141,384...42,158,882

G

MYC binding protein 2

increases expression

cyproconazole results in increased expression of MYCBP2 mRNA

NCBI chr15:79,937,354...80,175,432
Ensembl chr15:79,937,354...80,175,498

G

myosin Ib

decreases expression

cyproconazole results in decreased expression of MYO1B mRNA

NCBI chr 9:49,690,043...49,852,373
Ensembl chr 9:49,690,086...49,850,798

G

myosin VI

increases expression

cyproconazole results in increased expression of MYO6 mRNA

NCBI chr 8:81,087,157...81,242,022
Ensembl chr 8:81,087,139...81,239,292

G

N-acetylglucosamine kinase

increases expression

cyproconazole results in increased expression of NAGK mRNA

NCBI chr 4:116,281,179...116,293,870
Ensembl chr 4:116,281,328...116,313,137

G

nicotinate phosphoribosyltransferase

decreases expression

cyproconazole results in decreased expression of NAPRT mRNA

NCBI chr 7:107,576,645...107,580,102
Ensembl chr 7:107,576,627...107,580,102

G

N-acetyltransferase 8

decreases expression

cyproconazole results in decreased expression of NAT8 mRNA

NCBI chr 4:118,279,521...118,284,671
Ensembl chr 4:118,270,954...118,281,763

G

N-acetyltransferase 8 (GCN5-related) family member 1

decreases expression

cyproconazole results in decreased expression of NAT8F1 mRNA

NCBI chr 4:118,336,208...118,342,923
Ensembl chr 4:118,332,862...118,344,035

G

NBR1, autophagy cargo receptor

decreases expression

cyproconazole results in decreased expression of NBR1 mRNA

NCBI chr10:86,477,775...86,506,418
Ensembl chr10:86,478,290...86,506,412

G

N-myc downstream regulated 1

increases expression

cyproconazole results in increased expression of NDRG1 mRNA

NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880

G

N-deacetylase and N-sulfotransferase 1

decreases expression

cyproconazole results in decreased expression of NDST1 mRNA

NCBI chr18:54,136,887...54,199,545
Ensembl chr18:54,140,779...54,178,191

G

nebulette

increases expression

cyproconazole results in increased expression of NEBL mRNA

PMID:22334560 PMID:23970803

NCBI chr17:80,113,891...80,466,331
Ensembl chr17:80,118,543...80,466,210

G

NFE2 like bZIP transcription factor 2

increases activity

cyproconazole results in increased activity of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor I/B

decreases expression

cyproconazole results in decreased expression of NFIB mRNA

NCBI chr 5:96,759,208...96,974,001
Ensembl chr 5:96,764,653...96,975,479

G

NPL4 homolog, ubiquitin recognition factor

increases expression
multiple interactions

cyproconazole results in increased expression of NPLOC4 mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of NPLOC4 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of NPLOC4 mRNA

NCBI chr10:105,654,395...105,709,958
Ensembl chr10:105,654,812...105,709,913

G

NAD(P)H quinone dehydrogenase 1

increases expression
multiple interactions

cyproconazole results in increased expression of NQO1 mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of NQO1 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of NQO1 mRNA

PMID:25182419 PMID:29038839

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions
increases expression

[NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of ABCC3 mRNA]; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of ABCC3 protein]; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of AHR mRNA]; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of CD36 mRNA]; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of CDKN1A mRNA]; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of CYP2B10 protein]; [NR1I3 protein co-treated with NR1I2 protein] affects the reaction [cyproconazole results in increased expression of CYP2B10 mRNA]
cyproconazole results in increased expression of NR1I2 mRNA

PMID:28058446 PMID:29995386

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions
decreases expression
increases response to substance
affects response to substance

NR1I3 promotes the reaction [cyproconazole results in increased expression of CYP1A2 mRNA]; NR1I3 promotes the reaction [cyproconazole results in increased expression of CYP2B10 mRNA]; NR1I3 promotes the reaction [cyproconazole results in increased expression of CYP3A11 mRNA]; NR1I3 promotes the reaction [cyproconazole results in increased expression of POR mRNA]; NR1I3 protein mutant form inhibits the reaction [cyproconazole results in increased expression of CYP2B10 mRNA]; NR1I3 protein mutant form inhibits the reaction [cyproconazole results in increased expression of CYP2B10 protein]; NR1I3 protein mutant form inhibits the reaction [cyproconazole results in increased expression of GADD45B mRNA]
[NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of ABCC3 mRNA]; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of ABCC3 protein]; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of AHR mRNA]; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of CD36 mRNA]; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of CDKN1A mRNA]; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [cyproconazole results in increased expression of CYP2B10 protein]; [NR1I3 protein co-treated with NR1I2 protein] affects the reaction [cyproconazole results in increased expression of CYP2B10 mRNA]
cyproconazole results in decreased expression of NR1I3 mRNA
NR1I3 results in increased susceptibility to cyproconazole
NR1I3 protein affects the susceptibility to cyproconazole

PMID:17557908 PMID:23721867 PMID:25656644 PMID:25949234 PMID:28058446

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

neuronal cell adhesion molecule

increases expression

cyproconazole results in increased expression of NRCAM mRNA

NCBI chr 6:61,402,813...61,698,536
Ensembl chr 6:61,329,863...61,702,992

G

NSFL1 cofactor

increases expression

cyproconazole results in increased expression of NSFL1C mRNA

NCBI chr 3:139,978,306...140,002,876
Ensembl chr 3:139,978,301...140,002,870

G

NSL1 component of MIS12 kinetochore complex

increases expression

cyproconazole results in increased expression of NSL1 mRNA

PMID:22334560 PMID:23970803

NCBI chr13:102,649,050...102,674,059
Ensembl chr13:102,649,058...102,674,054

G

neurotrophic receptor tyrosine kinase 2

increases expression

cyproconazole results in increased expression of NTRK2 mRNA

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

2'-5'-oligoadenylate synthetase-like

increases expression

cyproconazole results in increased expression of OASL1 mRNA

NCBI chr12:41,682,900...41,695,641
Ensembl chr12:41,682,900...41,695,641

G

odorant binding protein 2A

decreases expression

cyproconazole results in decreased expression of OBP2A mRNA

PMID:22334560 PMID:23970803

NCBI chr 3:8,505,963...8,509,269
Ensembl chr 3:8,505,990...8,509,269

G

oligosaccharyltransferase complex subunit 4, non-catalytic

increases expression

cyproconazole results in increased expression of OST4 mRNA

NCBI chr 6:25,471,254...25,472,478

G

purinergic receptor P2X 4

increases expression

cyproconazole results in increased expression of P2RX4 mRNA

NCBI chr12:33,844,609...33,862,265
Ensembl chr12:33,844,396...33,862,253

G

3'-phosphoadenosine 5'-phosphosulfate synthase 2

increases expression

cyproconazole results in increased expression of PAPSS2 mRNA

NCBI chr 1:230,454,314...230,539,332
Ensembl chr 1:230,454,426...230,539,331

G

paired box 6

increases expression

cyproconazole results in increased expression of PAX6 mRNA

NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014

G

PBX homeobox 1

increases expression

cyproconazole results in increased expression of PBX1 mRNA

NCBI chr13:80,278,766...80,588,563
Ensembl chr13:80,278,770...80,588,594

G

pyruvate carboxylase

decreases expression

cyproconazole results in decreased expression of PCX mRNA

NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380

G

protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1

decreases expression

cyproconazole results in decreased expression of PCMTD1 mRNA

NCBI chr 5:12,284,711...12,355,680
Ensembl chr 5:12,284,711...12,354,899

G

phosphodiesterase 11A

decreases expression

cyproconazole results in decreased expression of PDE11A mRNA

NCBI chr 3:60,913,562...61,297,154
Ensembl chr 3:60,913,562...61,297,158

G

peptidase D

increases expression

cyproconazole results in increased expression of PEPD mRNA

NCBI chr 1:87,536,650...87,681,233
Ensembl chr 1:87,536,609...87,681,231

G

pipecolic acid and sarcosine oxidase

decreases expression

cyproconazole results in decreased expression of PIPOX mRNA

NCBI chr10:62,769,874...62,783,484
Ensembl chr10:62,769,900...62,782,370

G

phospholipase A2, group XIIA

increases expression

cyproconazole results in increased expression of PLA2G12A mRNA

NCBI chr 2:218,436,497...218,452,742
Ensembl chr 2:218,436,513...218,452,740

G

phospholipase A2 group VI

increases expression

cyproconazole results in increased expression of PLA2G6 mRNA

NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114

G

phospholipase B domain containing 1

increases expression

cyproconazole results in increased expression of PLBD1 mRNA

NCBI chr 4:169,472,983...169,529,277
Ensembl chr 4:169,472,983...169,529,277

G

perilipin 5

decreases expression

cyproconazole results in decreased expression of PLIN5 mRNA

NCBI chr 9:939,745...946,188
Ensembl chr 9:939,747...946,120

G

phosphomevalonate kinase

decreases expression

cyproconazole results in decreased expression of PMVK mRNA

NCBI chr 2:174,876,586...174,886,365
Ensembl chr 2:174,876,657...174,886,364

G

patatin-like phospholipase domain containing 7

decreases expression

cyproconazole results in decreased expression of PNPLA7 mRNA

NCBI chr 3:7,782,572...7,861,504
Ensembl chr 3:7,782,572...7,861,497

G

paraoxonase 3

increases expression

cyproconazole results in increased expression of PON3 mRNA

NCBI chr 4:33,356,983...33,383,681
Ensembl chr 4:33,349,168...33,383,855

G

cytochrome p450 oxidoreductase

increases expression
multiple interactions

cyproconazole results in increased expression of POR mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of POR mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of POR mRNA
NR1I3 promotes the reaction [cyproconazole results in increased expression of POR mRNA]

PMID:22334560 PMID:23970803 PMID:25656644 PMID:29038839

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

peroxisome proliferator activated receptor alpha

decreases expression

cyproconazole results in decreased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

PPARG coactivator 1 alpha

increases expression
multiple interactions

cyproconazole results in increased expression of PPARGC1A mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of PPARGC1A mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein phosphatase, Mg2+/Mn2+ dependent, 1K

decreases expression

cyproconazole results in decreased expression of PPM1K mRNA

NCBI chr 4:87,612,198...87,638,993
Ensembl chr 4:87,612,204...87,636,152

G

protein phosphatase 1 catalytic subunit gamma

increases expression

cyproconazole results in increased expression of PPP1CC mRNA

NCBI chr12:34,383,072...34,400,553
Ensembl chr12:34,383,072...34,400,553

G

protein phosphatase 1, regulatory subunit 42

increases expression

cyproconazole results in increased expression of PPP1R42 mRNA

NCBI chr 5:9,227,109...9,274,461
Ensembl chr 5:9,227,204...9,274,453

G

proteoglycan 4

increases expression

cyproconazole results in increased expression of PRG4 mRNA

NCBI chr13:62,487,257...62,504,657
Ensembl chr13:62,487,257...62,504,119

G

protein kinase AMP-activated catalytic subunit alpha 2

increases expression

cyproconazole results in increased expression of PRKAA2 mRNA

NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543

G

prolactin receptor

decreases expression

cyproconazole results in decreased expression of PRLR mRNA

NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718

G

pre-mRNA processing factor 19

increases expression

cyproconazole results in increased expression of PRPF19 mRNA

NCBI chr 1:207,541,582...207,552,664
Ensembl chr 1:207,541,595...207,552,662

G

prosaposin

increases expression

cyproconazole results in increased expression of PSAP mRNA

NCBI chr20:28,214,229...28,240,501
Ensembl chr20:28,214,271...28,240,498

G

presenilin 1

increases expression

cyproconazole results in increased expression of PSEN1 mRNA

NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650

G

proteasome 20S subunit alpha 5

increases expression

cyproconazole results in increased expression of PSMA5 mRNA

NCBI chr 2:195,896,369...195,919,733
Ensembl chr 2:195,896,365...195,919,731

G

proteasome 26S subunit, non-ATPase 12

increases expression

cyproconazole results in increased expression of PSMD12 mRNA

NCBI chr10:92,438,223...92,457,323
Ensembl chr10:92,438,298...92,457,287

G

PVR cell adhesion molecule

increases expression

cyproconazole results in increased expression of PVR mRNA

NCBI chr 1:79,561,294...79,576,700
Ensembl chr 1:79,546,879...79,576,715

G

RAB3 GTPase activating protein catalytic subunit 1

decreases expression

cyproconazole results in decreased expression of RAB3GAP1 mRNA

NCBI chr13:39,355,698...39,429,154
Ensembl chr13:39,352,247...39,429,169

G

Rac family small GTPase 2

increases expression

cyproconazole results in increased expression of RAC2 mRNA

NCBI chr 7:110,101,344...110,128,718
Ensembl chr 7:110,116,260...110,128,720

G

Rap guanine nucleotide exchange factor 4

increases expression

cyproconazole results in increased expression of RAPGEF4 mRNA

NCBI chr 3:56,809,388...57,101,332
Ensembl chr 3:56,809,270...57,102,316

G

retinoic acid receptor, beta

increases expression

cyproconazole results in increased expression of RARB mRNA

NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288

G

RB binding protein 8, endonuclease

increases expression

cyproconazole results in increased expression of RBBP8 mRNA

NCBI chr18:2,922,985...2,988,851
Ensembl chr18:2,921,286...2,988,846

G

reticulocalbin 2

increases expression

cyproconazole results in increased expression of RCN2 mRNA

NCBI chr 8:56,449,206...56,466,253
Ensembl chr 8:56,449,206...56,466,251

G

regucalcin

decreases expression

cyproconazole results in decreased expression of RGN mRNA

NCBI chr X:1,619,030...1,634,456
Ensembl chr X:1,619,032...1,634,450

G

rhomboid domain containing 1

increases expression

cyproconazole results in increased expression of RHBDD1 mRNA

NCBI chr 9:83,630,037...83,748,690
Ensembl chr 9:83,630,063...83,748,689

G

ras homolog family member C

decreases expression

cyproconazole results in decreased expression of RHOC mRNA

NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306

G

Rho family GTPase 3

decreases expression

cyproconazole results in decreased expression of RND3 mRNA

NCBI chr 3:35,571,929...35,589,283
Ensembl chr 3:35,571,143...35,589,327

G

RAS related

increases expression

cyproconazole results in increased expression of RRAS mRNA

NCBI chr 1:95,500,582...95,504,362
Ensembl chr 1:95,500,566...95,504,357

G

radical S-adenosyl methionine domain containing 2

increases expression

cyproconazole results in increased expression of RSAD2 mRNA

NCBI chr 6:43,046,514...43,059,737
Ensembl chr 6:43,047,658...43,059,699

G

S100 calcium binding protein A8

increases expression

cyproconazole results in increased expression of S100A8 mRNA

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

secretion associated, Ras related GTPase 1B

increases expression

cyproconazole results in increased expression of SAR1B mRNA

NCBI chr10:36,024,415...36,054,069
Ensembl chr10:36,024,382...36,054,066

G

SREBF chaperone

decreases expression

cyproconazole results in decreased expression of SCAP mRNA

NCBI chr 8:110,306,026...110,360,677
Ensembl chr 8:110,306,031...110,360,666

G

scavenger receptor class B, member 1

increases expression

cyproconazole results in increased expression of SCARB1 mRNA

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

stearoyl-CoA desaturase

increases expression

cyproconazole results in increased expression of SCD mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

SEC22 homolog B, vesicle trafficking protein

increases expression

cyproconazole results in increased expression of SEC22B mRNA

NCBI chr 2:185,500,029...185,520,811
Ensembl chr 2:185,500,004...185,522,026

G

SEC24 homolog D, COPII coat complex component

increases expression

cyproconazole results in increased expression of SEC24D mRNA

NCBI chr 2:211,418,557...211,526,588
Ensembl chr 2:211,418,623...211,526,587

G

SEC61 translocon subunit alpha 1

increases expression

cyproconazole results in increased expression of SEC61A1 mRNA

NCBI chr 4:120,973,519...120,987,871
Ensembl chr 4:120,960,626...120,987,925

G

SEC61 translocon subunit beta

increases expression

cyproconazole results in increased expression of SEC61B mRNA

NCBI chr 5:61,773,594...61,781,804
Ensembl chr 5:61,773,594...61,781,804

G

selenoprotein S

increases expression

cyproconazole results in increased expression of SELENOS mRNA

NCBI chr 1:119,659,779...119,669,546
Ensembl chr 1:119,659,751...119,669,833

G

serpin family A member 6

increases expression

cyproconazole results in increased expression of SERPINA6 mRNA

NCBI chr 6:122,780,040...122,790,274
Ensembl chr 6:122,780,043...122,790,349

G

serpin family A member 9

decreases expression

cyproconazole results in decreased expression of SERPINA9 mRNA

NCBI chr 6:122,918,819...122,936,000
Ensembl chr 6:122,918,880...122,936,000

G

serpin family F member 1

increases expression

cyproconazole results in increased expression of SERPINF1 mRNA

NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646

G

splicing factor 3b, subunit 2

decreases expression

cyproconazole results in decreased expression of SF3B2 mRNA

NCBI chr 1:202,570,423...202,590,774
Ensembl chr 1:202,570,423...202,590,759

G

sphingosine-1-phosphate lyase 1

increases expression

cyproconazole results in increased expression of SGPL1 mRNA

NCBI chr20:29,047,793...29,094,209
Ensembl chr20:29,047,796...29,094,084

G

sialic acid acetylesterase

increases expression

cyproconazole results in increased expression of SIAE mRNA

NCBI chr 8:37,318,724...37,354,004
Ensembl chr 8:37,318,747...37,353,996

G

signal-regulatory protein alpha

increases expression

cyproconazole results in increased expression of SIRPA mRNA

NCBI chr 3:116,819,730...116,858,099
Ensembl chr 3:116,819,726...116,858,098

G

solute carrier family 10 member 1

increases expression
decreases expression

cyproconazole results in increased expression of SLC10A1 mRNA
cyproconazole results in decreased expression of SLC10A1 protein

PMID:22334560 PMID:33150952

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 13 member 3

increases expression

cyproconazole results in increased expression of SLC13A3 mRNA

NCBI chr 3:154,141,878...154,204,604
Ensembl chr 3:154,141,872...154,204,606

G

solute carrier family 16, member 12

increases expression

cyproconazole results in increased expression of SLC16A12 mRNA

NCBI chr 1:232,184,004...232,262,170
Ensembl chr 1:232,185,907...232,262,141

G

solute carrier family 23 member 1

increases expression

cyproconazole results in increased expression of SLC23A1 mRNA

NCBI chr18:27,214,940...27,230,564
Ensembl chr18:27,216,281...27,230,697

G

solute carrier family 23 member 2

increases expression

cyproconazole results in increased expression of SLC23A2 mRNA

NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343

G

solute carrier family 25 member 15

decreases expression

cyproconazole results in decreased expression of SLC25A15 mRNA

NCBI chr16:69,631,581...69,654,869
Ensembl chr16:69,634,414...69,653,010

G

solute carrier family 25 member 22

decreases expression

cyproconazole results in decreased expression of SLC25A22 mRNA

NCBI chr 1:196,528,471...196,536,398
Ensembl chr 1:196,528,472...196,536,331

G

solute carrier family 25 member 37

increases expression

cyproconazole results in increased expression of SLC25A37 mRNA

NCBI chr15:44,534,280...44,576,697
Ensembl chr15:44,536,727...44,577,199

G

solute carrier family 39, member 11

increases expression

cyproconazole results in increased expression of SLC39A11 mRNA

NCBI chr10:98,275,958...98,697,042
Ensembl chr10:98,275,960...98,611,295

G

solute carrier family 48 member 1

increases expression

cyproconazole results in increased expression of SLC48A1 mRNA

NCBI chr 7:128,915,136...128,923,929
Ensembl chr 7:128,915,195...128,923,024

G

solute carrier organic anion transporter family, member 1a4

increases expression

cyproconazole results in increased expression of SLCO1A4 mRNA

PMID:22334560 PMID:23970803

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

G

slit guidance ligand 2

increases expression

cyproconazole results in increased expression of SLIT2 mRNA

NCBI chr14:62,616,337...62,955,934
Ensembl chr14:62,617,067...62,955,948

G

SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4

decreases expression

cyproconazole results in decreased expression of SMARCA4 mRNA

NCBI chr 8:20,167,717...20,258,975
Ensembl chr 8:20,167,717...20,258,975

G

sphingomyelin phosphodiesterase 3

increases expression

cyproconazole results in increased expression of SMPD3 mRNA

NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749

G

sorting nexin 17

decreases expression

cyproconazole results in decreased expression of SNX17 mRNA

NCBI chr 6:25,177,528...25,183,001
Ensembl chr 6:25,177,391...25,183,030

G

suppressor of cytokine signaling 3

affects expression

cyproconazole affects the expression of SOCS3 mRNA

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

signal peptidase complex subunit 2

increases expression

cyproconazole results in increased expression of SPCS2 mRNA

NCBI chr 1:154,163,724...154,183,152
Ensembl chr 1:154,163,724...154,183,186

G

sprouty RTK signaling antagonist 2

decreases expression

cyproconazole results in decreased expression of SPRY2 mRNA

NCBI chr15:82,692,291...82,697,408
Ensembl chr15:82,692,143...82,698,009

G

steroid 5 alpha-reductase 1

increases expression

cyproconazole results in increased expression of SRD5A1 mRNA

NCBI chr 1:33,686,069...33,720,468
Ensembl chr 1:33,686,391...33,720,461

G

SRP receptor subunit alpha

increases expression

cyproconazole results in increased expression of SRPRA mRNA

NCBI chr 8:33,560,365...33,566,458
Ensembl chr 8:33,560,348...33,566,470

G

sulfiredoxin 1

increases expression

cyproconazole results in increased expression of SRXN1 mRNA

NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448

G

steroidogenic acute regulatory protein

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of STAR mRNA

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

signal transducer and activator of transcription 5B

decreases activity

cyproconazole results in decreased activity of STAT5B protein

NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668

G

starch binding domain 1

increases expression

cyproconazole results in increased expression of STBD1 mRNA

PMID:22334560 PMID:29038839

NCBI chr14:15,470,452...15,473,857
Ensembl chr14:15,469,582...15,477,443

G

STT3 oligosaccharyltransferase complex catalytic subunit A

increases expression

cyproconazole results in increased expression of STT3A mRNA

NCBI chr 8:36,443,623...36,483,111
Ensembl chr 8:36,446,788...36,483,293

G

sulfotransferase family 1B member 1

decreases expression

cyproconazole results in decreased expression of SULT1B1 mRNA

NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483

G

T-box transcription factor 3

decreases expression

cyproconazole results in decreased expression of TBX3 mRNA

NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708

G

transforming growth factor alpha

increases expression

cyproconazole results in increased expression of TGFA mRNA

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

G

transforming growth factor, beta receptor 2

increases expression

cyproconazole results in increased expression of TGFBR2 mRNA

NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228

G

THO complex subunit 2

decreases expression

cyproconazole results in decreased expression of THOC2 mRNA

NCBI chr X:120,634,966...120,749,569
Ensembl chr X:120,634,968...120,749,513

G

translocase of inner mitochondrial membrane 10B

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of TIMM10B mRNA

NCBI chr 1:159,980,525...159,983,371
Ensembl chr 1:159,980,484...159,981,642

G

toll-like receptor 2

increases expression

cyproconazole results in increased expression of TLR2 mRNA

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

transmembrane 7 superfamily member 2

affects expression

cyproconazole affects the expression of TM7SF2 mRNA

NCBI chr 1:203,355,930...203,360,287
Ensembl chr 1:203,355,931...203,360,270

G

transmembrane 9 superfamily member 4

increases expression

cyproconazole results in increased expression of TM9SF4 mRNA

NCBI chr 3:141,627,128...141,675,386
Ensembl chr 3:141,627,346...141,675,386

G

transmembrane BAX inhibitor motif containing 4

increases expression

cyproconazole results in increased expression of TMBIM4 mRNA

NCBI chr 7:55,718,690...55,733,277
Ensembl chr 7:55,718,699...55,742,773

G

transmembrane p24 trafficking protein 10

increases expression

cyproconazole results in increased expression of TMED10 mRNA

NCBI chr 6:104,991,843...105,026,705
Ensembl chr 6:104,991,838...105,026,753

G

transmembrane p24 trafficking protein 3

increases expression

cyproconazole results in increased expression of TMED3 mRNA

NCBI chr 8:90,241,516...90,249,429
Ensembl chr 8:90,241,516...90,249,346

G

transmembrane protein 109

increases expression

cyproconazole results in increased expression of TMEM109 mRNA

NCBI chr 1:207,519,628...207,530,245
Ensembl chr 1:207,519,624...207,530,215

G

transmembrane protein 167A

increases expression

cyproconazole results in increased expression of TMEM167 mRNA

NCBI chr 2:21,197,799...21,216,746
Ensembl chr 2:21,197,786...21,212,099

G

transmembrane protein 176A

increases expression

cyproconazole results in increased expression of TMEM176A mRNA

NCBI chr 4:77,774,940...77,778,620
Ensembl chr 4:77,774,843...77,778,620

G

transmembrane protein 176B

increases expression

cyproconazole results in increased expression of TMEM176B mRNA

NCBI chr 4:77,766,928...77,774,740
Ensembl chr 4:77,766,928...77,774,384

G

transmembrane protein 43

increases expression

cyproconazole results in increased expression of TMEM43 mRNA

NCBI chr 4:123,977,680...123,992,823
Ensembl chr 4:123,977,625...123,992,825

G

thiol methyltransferase 1A

increases expression

cyproconazole results in increased expression of TMT1A mRNA

NCBI chr 7:131,452,099...131,460,154
Ensembl chr 7:131,451,641...131,460,154

G

thioredoxin-related transmembrane protein 2

increases expression

cyproconazole results in increased expression of TMX2 mRNA

NCBI chr 3:69,754,937...69,762,587
Ensembl chr 3:69,754,939...69,762,587

G

TNF receptor superfamily member 19

increases expression

cyproconazole results in increased expression of TNFRSF19 mRNA

PMID:22334560 PMID:23970803

NCBI chr15:35,092,206...35,158,472
Ensembl chr15:35,092,206...35,180,795

G

tankyrase 2

decreases expression

cyproconazole results in decreased expression of TNKS2 mRNA

NCBI chr 1:234,567,888...234,621,079
Ensembl chr 1:234,567,858...234,621,079

G

torsin family 1, member B

increases expression

cyproconazole results in increased expression of TOR1B mRNA

NCBI chr 3:14,243,181...14,249,279
Ensembl chr 3:14,243,243...14,249,272

G

teashirt zinc finger homeobox 1

increases expression

cyproconazole results in increased expression of TSHZ1 mRNA

NCBI chr18:77,376,399...77,452,815
Ensembl chr18:77,377,394...77,453,509

G

tetratricopeptide repeat domain 39C

decreases expression

cyproconazole results in decreased expression of TTC39C mRNA

NCBI chr18:3,768,802...3,887,932
Ensembl chr18:3,805,183...3,887,930

G

thioredoxin 1

increases expression

cyproconazole results in increased expression of TXN1 mRNA

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

G

thioredoxin domain containing 17

increases expression

cyproconazole results in increased expression of TXNDC17 mRNA

NCBI chr10:56,832,749...56,835,721

G

ubiquitin-like modifier activating enzyme 5

increases expression

cyproconazole results in increased expression of UBA5 mRNA

NCBI chr 8:104,665,241...104,680,915
Ensembl chr 8:104,665,046...104,680,894

G

ubiquitin B

increases expression

cyproconazole results in increased expression of UBB mRNA

NCBI chr10:47,247,630...47,249,335
Ensembl chr10:47,245,637...47,249,333

G

ubinuclein 1

decreases expression

cyproconazole results in decreased expression of UBN1 mRNA

NCBI chr10:10,496,576...10,532,010
Ensembl chr10:10,496,576...10,532,010

G

ubiquilin 2

multiple interactions
increases expression

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of UBQLN2 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of UBQLN2 mRNA
cyproconazole results in increased expression of UBQLN2 mRNA

NCBI chr X:17,853,086...17,856,505
Ensembl chr X:17,853,114...17,856,505

G

UDP glucuronosyltransferase family 1 member A1

increases expression
multiple interactions

cyproconazole results in increased expression of UGT1A1 mRNA
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of UGT1A1 mRNA; [cyproconazole co-treated with epoxiconazole] results in increased expression of UGT1A1 mRNA

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A9

increases expression

cyproconazole results in increased expression of UGT1A9 mRNA

NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase 2 family, polypeptide B1

increases expression
multiple interactions

cyproconazole results in increased expression of UGT2B1 mRNA
[cyproconazole co-treated with epoxiconazole] results in increased expression of UGT2B1 mRNA

NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986

G

UDP glucuronosyltransferase family 2 member B7

decreases expression
increases expression

cyproconazole results in decreased expression of UGT2B7 protein
cyproconazole results in increased expression of UGT2B34 mRNA

PMID:22334560 PMID:29995386

NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604

G

unc-51 like autophagy activating kinase 2

increases expression

cyproconazole results in increased expression of ULK2 mRNA

NCBI chr10:46,451,578...46,530,462
Ensembl chr10:46,454,030...46,530,407

G

vasodilator-stimulated phosphoprotein

decreases expression

cyproconazole results in decreased expression of VASP mRNA

NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061

G

VPS29 retromer complex component

increases expression

cyproconazole results in increased expression of VPS29 mRNA

NCBI chr12:34,208,911...34,217,977
Ensembl chr12:34,207,263...34,217,964

G

vesicle transport through interaction with t-SNAREs 1B

increases expression

cyproconazole results in increased expression of VTI1B mRNA

NCBI chr 6:97,957,700...97,976,491
Ensembl chr 6:97,961,346...97,976,465

G

vitronectin

decreases expression

cyproconazole results in decreased expression of VTN mRNA

NCBI chr10:63,394,732...63,397,812
Ensembl chr10:63,394,719...63,397,810

G

WD repeat domain 18

increases expression

cyproconazole results in increased expression of WDR18 mRNA

NCBI chr 7:9,740,245...9,748,041
Ensembl chr 7:9,739,604...9,748,070

G

X-linked inhibitor of apoptosis

decreases expression

cyproconazole results in decreased expression of XIAP mRNA

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

G

X-ray repair cross complementing 1

increases expression
multiple interactions

cyproconazole results in increased expression of XRCC1 mRNA
[cyproconazole co-treated with epoxiconazole] results in increased expression of XRCC1 mRNA

NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701

G

X-ray repair cross complementing 5

multiple interactions

[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of XRCC5 mRNA

NCBI chr 9:73,955,216...74,044,020
Ensembl chr 9:73,955,216...74,044,018

G

Yip1 domain family, member 5

increases expression

cyproconazole results in increased expression of YIPF5 mRNA

NCBI chr18:32,123,814...32,136,947
Ensembl chr18:32,123,842...32,157,642

G

zinc finger and BTB domain containing 16

increases expression

cyproconazole results in increased expression of ZBTB16 mRNA

NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011

labetalol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 4

decreases activity

Labetalol results in decreased activity of ABCB4 protein

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

angiotensin converting enzyme 2

increases activity

Labetalol results in increased activity of ACE2 protein

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

adrenoceptor beta 1

decreases activity
affects binding
increases activity
multiple interactions

Labetalol results in decreased activity of ADRB1 protein
Labetalol binds to ADRB1 protein
Labetalol results in increased activity of ADRB1 protein
[Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP; CGP 20712A inhibits the reaction [[Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [Labetalol results in increased activity of ADRB1 protein]
Labetalol binds to and results in decreased activity of ADRB1 protein; Labetalol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Labetalol inhibits the reaction [Dihydroalprenolol binds to ADRB1 protein]

PMID:2462161 PMID:2567112 PMID:11425575 PMID:11483288 PMID:12761341

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

decreases activity
affects binding
multiple interactions

Labetalol results in decreased activity of ADRB2 protein
Labetalol binds to ADRB2 protein
[Labetalol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Labetalol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Labetalol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein
Labetalol binds to and results in decreased activity of ADRB2 protein; Labetalol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Labetalol inhibits the reaction [Dihydroalprenolol binds to ADRB2 protein]

PMID:2462161 PMID:2567112 PMID:11425575 PMID:11483288 PMID:17925438

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

angiotensinogen

decreases expression

Labetalol results in decreased expression of AGT protein

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

arginine vasopressin

multiple interactions

[Labetalol co-treated with Isoflurane] results in increased expression of AVP protein

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

mitogen activated protein kinase 1

multiple interactions

[Labetalol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[Labetalol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

natriuretic peptide A

decreases activity

Labetalol results in decreased activity of NPPA protein

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

prolactin

multiple interactions
increases expression

carbidopa, levodopa drug combination inhibits the reaction [Labetalol results in increased expression of PRL protein]

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

renin

multiple interactions
decreases activity

[Labetalol co-treated with Isoflurane] results in increased expression of REN protein
Labetalol results in decreased activity of REN protein

PMID:1897344 PMID:2524958 PMID:7013770 PMID:7988622

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

UDP glucuronosyltransferase family 1 member A1

multiple interactions

[Uridine Diphosphate Glucuronic Acid co-treated with UGT1A1 protein] results in increased glucuronidation of Labetalol

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 2 member B7

multiple interactions

[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol; Fluconazole inhibits the reaction [[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol]

NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604

lobaplatin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

baculoviral IAP repeat-containing 2

increases degradation

Lobaplatin increases degradation of BIRC2 protein in human nasopharyngeal carcinoma cells

RGD

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 3

increases degradation

Lobaplatin increases degradation of BIRC3 protein in human nasopharyngeal carcinoma cells

RGD

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

misoprostol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adenylate cyclase activating polypeptide 1

multiple interactions

Misoprostol inhibits the reaction [ADCYAP1 protein results in increased secretion of Histamine]

NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773

G

BCL2 associated X, apoptosis regulator

multiple interactions

Misoprostol inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

caspase 3

multiple interactions

Misoprostol inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

Misoprostol inhibits the reaction [Cisplatin results in decreased expression of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cholinergic receptor, muscarinic 1

multiple interactions

Misoprostol inhibits the reaction [(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride binds to and results in increased activity of CHRM1 protein]

NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356

G

gastrin

multiple interactions
decreases activity

Misoprostol inhibits the reaction [GAST protein results in increased secretion of Histamine]
Misoprostol results in decreased activity of GAST protein

PMID:2459756 PMID:11164953

NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496

G

interleukin 10

multiple interactions

Misoprostol inhibits the reaction [[IL23A co-treated with IL1B] results in increased expression of IL10]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

multiple interactions

Misoprostol inhibits the reaction [[IL23A co-treated with IL1B] results in increased expression of IL10]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 23 subunit alpha

multiple interactions
increases expression

Misoprostol inhibits the reaction [[IL23A co-treated with IL1B] results in increased expression of IL10]
Misoprostol results in increased expression of IL23A mRNA

NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923

G

prostaglandin E receptor 1

multiple interactions

[L-335677 binds to and results in decreased activity of PTGER1 protein] inhibits the reaction [Misoprostol results in increased susceptibility to Formaldehyde]

NCBI chr19:24,470,258...24,473,687
Ensembl chr19:24,467,532...24,473,559

G

prostaglandin E receptor 2

multiple interactions

[6-isopropoxy-9-oxoxanthene-2-carboxylic acid binds to and results in decreased activity of PTGER2 protein] inhibits the reaction [Misoprostol results in increased susceptibility to Formaldehyde]

NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714

G

prostaglandin E receptor 3

multiple interactions

[L-826266 binds to and results in decreased activity of PTGER3 protein] inhibits the reaction [Misoprostol results in decreased susceptibility to Formaldehyde]

NCBI chr 2:246,606,131...246,750,970
Ensembl chr 2:246,606,183...246,684,434

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide inhibits the reaction [Misoprostol results in increased expression of PTGS2 protein]; Indomethacin inhibits the reaction [Misoprostol results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

tachykinin, precursor 1

multiple interactions

Misoprostol promotes the reaction [Kallidin results in increased secretion of TAC1 protein]

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

G

tumor necrosis factor

multiple interactions

Misoprostol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

nadolol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 1

multiple interactions

Nadolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions

[Nadolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

interleukin 10

multiple interactions

[Nadolol co-treated with Mifepristone] promotes the reaction [methyldithiocarbamate promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 12B

multiple interactions

[Nadolol co-treated with Mifepristone] inhibits the reaction [methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]]

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

solute carrier family 22 member 1

multiple interactions

Nadolol inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

ractopamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 2

increases activity

ractopamine results in increased activity of ADRB2 protein

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

estrogen receptor 1

multiple interactions

ractopamine binds to and results in increased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

potassium voltage-gated channel subfamily H member 2

decreases activity

ractopamine results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

S-butyl-DL-homocysteine (S,R)-sulfoximine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 1

affects localization
multiple interactions

Buthionine Sulfoximine affects the localization of ABCC1 protein mutant form
[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [ABCC1 results in decreased susceptibility to arsenite]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [ABCC1 results in decreased susceptibility to monomethylarsonous acid analog]; Buthionine Sulfoximine analog inhibits the reaction [Acetylcysteine promotes the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin]]; Buthionine Sulfoximine inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Buthionine Sulfoximine inhibits the reaction [ABCC1 results in decreased susceptibility to arsenite]; Buthionine Sulfoximine inhibits the reaction [ABCC1 results in decreased susceptibility to methylarsine analog]

PMID:15180633 PMID:15473893 PMID:15581632 PMID:21918036

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

apoptotic chromatin condensation inducer 1

increases expression

Buthionine Sulfoximine results in increased expression of ACIN1 protein

NCBI chr15:28,102,112...28,147,001
Ensembl chr15:28,102,112...28,147,001

G

actin, beta

decreases expression

Buthionine Sulfoximine results in decreased expression of ACTB mRNA

NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877

G

adducin 3

increases expression

Buthionine Sulfoximine results in increased expression of ADD3 mRNA

NCBI chr 1:252,147,341...252,255,126
Ensembl chr 1:252,147,386...252,255,124

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

multiple interactions

Buthionine Sulfoximine promotes the reaction [Ethanol results in increased expression of ADH1 mRNA]

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

aminoacyl tRNA synthetase complex-interacting multifunctional protein 1

increases expression

Buthionine Sulfoximine results in increased expression of AIMP1 mRNA

NCBI chr 2:221,151,907...221,175,458
Ensembl chr 2:221,151,904...221,175,728

G

AKT serine/threonine kinase 1

multiple interactions

Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium results in increased phosphorylation of AKT1 protein]
Buthionine Sulfoximine promotes the reaction [arsenite results in increased phosphorylation of AKT1 protein]

PMID:24449419 PMID:36343453

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aminolevulinate dehydratase

decreases activity

Buthionine Sulfoximine results in decreased activity of ALAD protein

NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474

G

5'-aminolevulinate synthase 1

multiple interactions

Buthionine Sulfoximine inhibits the reaction [1,2,4-trichlorobenzene results in increased activity of ALAS1 protein]

NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917

G

albumin

multiple interactions

[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of ALB mRNA

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldolase, fructose-bisphosphate A

increases expression

Buthionine Sulfoximine results in increased expression of ALDOA mRNA; Buthionine Sulfoximine results in increased expression of ALDOA protein

PMID:11841787 PMID:23736079

NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182

G

alpha-1-microglobulin/bikunin precursor

multiple interactions

[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of AMBP mRNA

NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331

G

apurinic/apyrimidinic endodeoxyribonuclease 1

increases expression

Buthionine Sulfoximine results in increased expression of APEX1 protein

NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785

G

apolipoprotein H

multiple interactions

[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of APOH mRNA

NCBI chr10:93,342,435...93,356,334
Ensembl chr10:93,310,977...93,356,329

G

amyloid beta precursor protein

multiple interactions

(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein]; (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein]; (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

aryl hydrocarbon receptor nuclear translocator

decreases expression

Buthionine Sulfoximine results in decreased expression of ARNT protein

NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580

G

ATP synthase F1 subunit beta

increases expression

Buthionine Sulfoximine results in increased expression of ATP5F1B mRNA

NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273

G

ataxin 1

affects localization
multiple interactions

Buthionine Sulfoximine affects the localization of ATXN1 protein mutant form
Buthionine Sulfoximine promotes the reaction [Hydrogen Peroxide affects the localization of ATXN1 protein mutant form]; Buthionine Sulfoximine promotes the reaction [tert-Butylhydroperoxide affects the localization of ATXN1 protein mutant form]

NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360

G

Axl receptor tyrosine kinase

increases expression

Buthionine Sulfoximine results in increased expression of AXL mRNA

NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265

G

antizyme inhibitor 1

decreases expression

Buthionine Sulfoximine results in decreased expression of AZIN1 mRNA

NCBI chr 7:69,654,773...69,681,578
Ensembl chr 7:69,654,663...69,681,578

G

BCL2 associated X, apoptosis regulator

multiple interactions

[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in decreased expression of BAX protein; Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in decreased expression of BAX protein]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

Buthionine Sulfoximine results in decreased expression of BCL2 mRNA
Buthionine Sulfoximine promotes the reaction [cyanoginosin LR results in decreased expression of BCL2 protein]
[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in increased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in increased expression of BCL2 protein]
Sodium Selenite promotes the reaction [Buthionine Sulfoximine results in decreased expression of BCL2 mRNA]

PMID:11341981 PMID:17989939 PMID:25410294

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone morphogenetic protein 1

decreases expression

Buthionine Sulfoximine results in decreased expression of BMP1 mRNA

NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776

G

calreticulin

increases expression

Buthionine Sulfoximine results in increased expression of CALR protein

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

caspase 3

multiple interactions
increases expression
increases activity

4-amylcinnamoylanthranilic acid inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP3 protein]; Glutathione inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP3 protein]; Sodium Selenite promotes the reaction [Buthionine Sulfoximine results in increased expression of CASP3 mRNA]
[O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate co-treated with Buthionine Sulfoximine] results in increased cleavage of CASP3 protein; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide results in increased activity of CASP3 protein]; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased activity of CASP3 protein]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of and results in increased cleavage of CASP3 protein]; Buthionine Sulfoximine results in increased expression of and results in increased cleavage of CASP3 protein
[Buthionine Sulfoximine co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [monomethylarsonic acid co-treated with Buthionine Sulfoximine] results in increased activity of CASP3 protein; Buthionine Sulfoximine inhibits the reaction [Cacodylic Acid results in increased activity of CASP3 protein]; Buthionine Sulfoximine promotes the reaction [Vitamin K 3 results in increased activity of CASP3 protein]

PMID:10673743 PMID:15276415 PMID:15963344 PMID:16310883 PMID:17200146 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 4

multiple interactions

Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased activity of CASP4 protein]

NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092

G

caspase 7

multiple interactions

Buthionine Sulfoximine promotes the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate affects the cleavage of CASP7 protein]

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

multiple interactions

[Buthionine Sulfoximine co-treated with arsenic trioxide] results in increased cleavage of CASP8 protein; pyrazolanthrone inhibits the reaction [[Buthionine Sulfoximine co-treated with arsenic trioxide] results in increased cleavage of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases activity

4-amylcinnamoylanthranilic acid inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP9 protein]; Glutathione inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

decreases activity
multiple interactions

Buthionine Sulfoximine results in decreased activity of CAT protein
Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]; CAT inhibits the reaction [Buthionine Sulfoximine results in decreased abundance of Glutathione]; CAT inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]; CAT inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]; CD36 mRNA promotes the reaction [CAT inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]]

PMID:21620807 PMID:21772021 PMID:26187465

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 11

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of CCL11 mRNA

PMID:22407903 PMID:27421576

NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of CCL2 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CCL2 mRNA; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CCL2 mRNA]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CCL2 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CCL2 mRNA]

PMID:22407903 PMID:26177832 PMID:31294483 PMID:35123994

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

multiple interactions

Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]]

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cyclin D1

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of CCND1 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of CCND1 protein]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

CD163 molecule

multiple interactions

[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA]

NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878

G

CD36 molecule

increases expression
multiple interactions

Buthionine Sulfoximine results in increased expression of CD36 protein
[pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CD36 mRNA; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]; CAT inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]; CD36 mRNA promotes the reaction [Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]]; CD36 mRNA promotes the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]; CD36 mRNA promotes the reaction [CAT inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]]; PPARG mRNA promotes the reaction [Tamoxifen inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]]; Tamoxifen inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]

PMID:26187465 PMID:27358406 PMID:28263783

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

CD59b molecule

increases mutagenesis

Buthionine Sulfoximine results in increased mutagenesis of CD59 gene

NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847

G

Cd68 molecule

multiple interactions

[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD68 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD68 mRNA]

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

CD86 molecule

increases expression

Buthionine Sulfoximine results in increased expression of CD86 protein

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of CDKN1A protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of CDKN1A protein]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of CDKN1B protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of CDKN1B protein]

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

checkpoint kinase 2

multiple interactions

Buthionine Sulfoximine promotes the reaction [potassium chromate(VI) results in increased expression of CHEK2 protein modified form]

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

calcium homeostasis endoplasmic reticulum protein

increases expression

Buthionine Sulfoximine results in increased expression of CHERP protein

NCBI chr16:17,367,455...17,380,507
Ensembl chr16:17,367,455...17,380,507

G

collagen type I alpha 1 chain

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of COL1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of COL1A1 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of COL1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of COL1A1 protein]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

multiple interactions

Buthionine Sulfoximine promotes the reaction [CYP2E1 protein results in increased expression of COL1A2 mRNA]

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type V alpha 3 chain

decreases expression

Buthionine Sulfoximine results in decreased expression of COL5A3 mRNA

NCBI chr 8:19,304,564...19,349,809
Ensembl chr 8:19,304,571...19,349,853

G

cytochrome c oxidase subunit 4i1

increases expression

Buthionine Sulfoximine results in increased expression of COX4I1 mRNA

NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921

G

chromosome segregation 1 like

increases expression

Buthionine Sulfoximine results in increased expression of CSE1L protein

NCBI chr 3:155,641,104...155,678,866
Ensembl chr 3:155,641,166...155,678,865

G

colony stimulating factor 1

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CSF1 mRNA]

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

C-X-C motif chemokine ligand 1

multiple interactions

[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL1 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL1 mRNA]

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 12

decreases expression
increases expression
multiple interactions

Buthionine Sulfoximine results in decreased expression of CXCL12 mRNA
Buthionine Sulfoximine results in increased expression of CXCL12 mRNA
Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CXCL12 mRNA]

PMID:15878706 PMID:35123994

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 2

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; Alprostadil inhibits the reaction [[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL2 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL2 mRNA]

PMID:23986454 PMID:26177832 PMID:27421576 PMID:28263783 PMID:31294483

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

multiple interactions

[Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CXCL1 mRNA; Buthionine Sulfoximine promotes the reaction [Tobacco Smoke Pollution results in increased secretion of and results in increased expression of CXCL1 protein]

PMID:26149495 PMID:31294483

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

C-X-C motif chemokine receptor 4

decreases expression

Buthionine Sulfoximine results in decreased expression of CXCR4 mRNA

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases activity
increases activity

Buthionine Sulfoximine affects the reaction [Curcumin affects the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]]; Buthionine Sulfoximine inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]
Buthionine Sulfoximine results in decreased activity of CYP1A1 protein
Buthionine Sulfoximine results in increased activity of CYP1A1 protein
[Buthionine Sulfoximine co-treated with 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide] inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]; [Buthionine Sulfoximine co-treated with Cadmium Chloride] results in increased expression of CYP1A1 mRNA; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of CYP1A1 mRNA; Buthionine Sulfoximine inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]; Buthionine Sulfoximine promotes the reaction [andrographolide affects the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [chromium trioxide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [chromium trioxide results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Copper inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [Lead inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Mercury inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
Buthionine Sulfoximine inhibits the reaction [Methylcholanthrene results in increased activity of CYP1A1 protein]; Buthionine Sulfoximine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

PMID:9756946 PMID:16274885 PMID:16906435 PMID:18078826 PMID:19033395 More...

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases response to substance
multiple interactions

CYP2E1 protein results in increased susceptibility to Buthionine Sulfoximine; CYP2E1 results in increased susceptibility to Buthionine Sulfoximine
Buthionine Sulfoximine promotes the reaction [[CYP2E1 protein co-treated with Vitamin K 3] results in increased expression of KLF6 protein]; Buthionine Sulfoximine promotes the reaction [CYP2E1 protein results in increased expression of COL1A2 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin promotes the reaction [CYP2E1 protein results in increased susceptibility to Buthionine Sulfoximine]; Zinc Sulfate inhibits the reaction [CYP2E1 results in increased susceptibility to Buthionine Sulfoximine]

PMID:10498651 PMID:12086689 PMID:12566070 PMID:22486562

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[CYP3A4 protein co-treated with Buthionine Sulfoximine] results in decreased abundance of Glutathione; Buthionine Sulfoximine promotes the reaction [[CYP3A4 protein co-treated with neferine] results in decreased abundance of Glutathione]; neferine promotes the reaction [[CYP3A4 protein co-treated with Buthionine Sulfoximine] results in decreased abundance of Glutathione]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

DAB adaptor protein 1

decreases expression

Buthionine Sulfoximine results in decreased expression of DAB1 mRNA

NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552

G

aspartyl-tRNA synthetase 1

increases expression

Buthionine Sulfoximine results in increased expression of DARS1 protein

NCBI chr13:39,857,936...39,913,055
Ensembl chr13:39,857,936...39,913,116

G

DNA-damage inducible transcript 3

multiple interactions

Buthionine Sulfoximine promotes the reaction [Curcumin results in increased expression of DDIT3 mRNA]; Buthionine Sulfoximine promotes the reaction [Curcumin results in increased expression of DDIT3 protein]; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of DDIT3 protein]

PMID:17171638 PMID:25341683

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

diacylglycerol O-acyltransferase 2

decreases expression

Buthionine Sulfoximine results in decreased expression of DGAT2 mRNA

NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428

G

iodothyronine deiodinase 2

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Colforsin results in increased activity of DIO2 protein]

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

iodothyronine deiodinase 3

increases activity

Buthionine Sulfoximine results in increased activity of DIO3 protein

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

dihydrolipoamide dehydrogenase

increases expression

Buthionine Sulfoximine results in increased expression of DLD protein

NCBI chr 6:47,904,153...47,924,814
Ensembl chr 6:47,903,914...47,924,795

G

enoyl-CoA hydratase 1

increases expression

Buthionine Sulfoximine results in increased expression of ECH1 mRNA

NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795

G

eukaryotic translation elongation factor 1 alpha 1

increases expression

Buthionine Sulfoximine results in increased expression of EEF1A1 mRNA

NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839

G

eukaryotic translation elongation factor 1 beta 2

increases expression

Buthionine Sulfoximine results in increased expression of EEF1B2 mRNA

NCBI chr 9:64,580,163...64,582,737
Ensembl chr 9:64,579,893...64,582,737

G

epidermal growth factor

multiple interactions

Buthionine Sulfoximine promotes the reaction [arsenite results in increased expression of and results in increased secretion of EGF protein]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

early growth response 1

multiple interactions

Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of EGR1 mRNA]

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

eukaryotic translation initiation factor 1A

decreases expression

Buthionine Sulfoximine results in decreased expression of EIF1A mRNA

NCBI chr18:39,325,695...39,338,043
Ensembl chr18:39,325,202...39,338,696

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased phosphorylation of EIF2AK3 protein]

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2B subunit delta

decreases expression

Buthionine Sulfoximine results in decreased expression of EIF2B4 mRNA

NCBI chr 6:25,183,177...25,188,832
Ensembl chr 6:25,183,186...25,188,829

G

eukaryotic translation initiation factor 3, subunit G

decreases expression

Buthionine Sulfoximine results in decreased expression of EIF3G mRNA

NCBI chr 8:19,429,728...19,433,760
Ensembl chr 8:19,429,643...19,433,808

G

extended synaptotagmin 1

decreases expression

Buthionine Sulfoximine results in decreased expression of ESYT1 mRNA

NCBI chr 7:928,848...946,199
Ensembl chr 7:928,848...946,199

G

eukaryotic translation termination factor 1

increases expression

Buthionine Sulfoximine results in increased expression of ETF1 mRNA

NCBI chr18:26,502,413...26,530,753
Ensembl chr18:26,504,080...26,530,810

G

enhancer of zeste 1 polycomb repressive complex 2 subunit

decreases expression

Buthionine Sulfoximine results in decreased expression of EZH1 mRNA

NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921

G

Fas cell surface death receptor

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Copper deficiency results in increased expression of FAS mRNA]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of FASL mRNA

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

FKBP prolyl isomerase 5

increases expression

Buthionine Sulfoximine results in increased expression of FKBP5 protein

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

Fms related receptor tyrosine kinase 1

increases expression

Buthionine Sulfoximine results in increased expression of FLT1 mRNA

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

flavin containing dimethylaniline monoxygenase 3

multiple interactions

Buthionine Sulfoximine inhibits the reaction [FMO3 protein results in increased susceptibility to Thiourea]

NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028

G

fibronectin 1

multiple interactions

[Buthionine Sulfoximine results in decreased abundance of Glutathione] promotes the reaction [manganese chloride results in increased expression of and results in increased secretion of FN1 protein]

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

Buthionine Sulfoximine inhibits the reaction [Sodium Selenite results in increased expression of FOS mRNA]; Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of FOS mRNA]; Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of FOS mRNA]

PMID:7743507 PMID:15520183 PMID:18449455 PMID:21825963

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 1, AP-1 transcription factor subunit

multiple interactions

Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of FOSL1 mRNA]
Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of FOSL1 mRNA]

PMID:15520183 PMID:19010381

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

forkhead box P3

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of FOXP3 mRNA
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of FOXP3 mRNA

PMID:23986454 PMID:26177832

NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838

G

ferritin heavy chain 1

multiple interactions
increases expression

Buthionine Sulfoximine promotes the reaction [3-O-caffeoyl-1-methylquinic acid results in increased expression of FTH1 mRNA]
Buthionine Sulfoximine results in increased expression of FTH1 mRNA

PMID:15878706 PMID:16631525

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

glucose-6-phosphate dehydrogenase

increases expression

Buthionine Sulfoximine results in increased expression of G6PD mRNA

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions
increases expression

[Buthionine Sulfoximine results in decreased abundance of Glutathione] promotes the reaction [1,2-naphthoquinone binds to GAPDH protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] promotes the reaction [1,2-naphthoquinone results in decreased activity of GAPDH protein]
Buthionine Sulfoximine results in increased expression of GAPDH mRNA

PMID:15878706 PMID:21827172

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

GATA binding protein 3

multiple interactions
decreases expression

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of GATA3 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of GATA3 mRNA
Buthionine Sulfoximine results in decreased expression of GATA3 mRNA

PMID:22407903 PMID:23986454 PMID:26177832 PMID:27421576

NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391

G

GC, vitamin D binding protein

multiple interactions

[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of GC mRNA

NCBI chr14:18,632,146...18,667,563
Ensembl chr14:18,632,135...18,667,567

G

glutamate-cysteine ligase, catalytic subunit

increases activity
decreases expression
increases expression
multiple interactions
decreases activity

Buthionine Sulfoximine results in increased activity of GCLC protein
Buthionine Sulfoximine results in decreased expression of GCLC protein
Buthionine Sulfoximine results in increased expression of GCLC mRNA
[Buthionine Sulfoximine results in decreased activity of GCLC protein] inhibits the reaction [indenoindole results in increased abundance of Glutathione]; [Buthionine Sulfoximine results in decreased activity of GCLC protein] which results in decreased abundance of Glutathione; [Thiabendazole co-treated with Buthionine Sulfoximine] results in increased activity of GCLC protein; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of GCLC mRNA]; Buthionine Sulfoximine inhibits the reaction [GCLC protein results in decreased susceptibility to naphthalene]; Buthionine Sulfoximine inhibits the reaction [Hypochlorous Acid results in increased expression of GCLC mRNA]; Buthionine Sulfoximine inhibits the reaction [naphthalene results in increased activity of GCLC protein]; Buthionine Sulfoximine promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of GCLC mRNA]
Buthionine Sulfoximine inhibits the reaction [[Lithocholic Acid results in increased expression of GCLC protein] which results in increased abundance of Glutathione]; Buthionine Sulfoximine inhibits the reaction [GCLC results in decreased susceptibility to Cadmium Chloride]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in decreased expression of GCLC protein]
[Buthionine Sulfoximine co-treated with Carmustine] results in decreased activity of GCLC protein; [Buthionine Sulfoximine results in decreased activity of [GCLC protein binds to GCLM protein]] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]]; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of GCLC protein; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of GCLC mRNA]; Buthionine Sulfoximine inhibits the reaction [GCLC protein results in increased chemical synthesis of gamma-glutamylcysteine]; Buthionine Sulfoximine inhibits the reaction [Microcystins analog results in increased expression of GCLC mRNA]

PMID:7955076 PMID:10900227 PMID:10915739 PMID:10978506 PMID:11019651 More...

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression
multiple interactions

Buthionine Sulfoximine results in increased expression of GCLM mRNA
Buthionine Sulfoximine inhibits the reaction [[Lithocholic Acid results in increased expression of GCLM protein] which results in increased abundance of Glutathione]
[Buthionine Sulfoximine results in decreased activity of [GCLC protein binds to GCLM protein]] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]]

PMID:10978506 PMID:17724089 PMID:19010381 PMID:22864849

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

growth differentiation factor 15

increases expression
multiple interactions

Buthionine Sulfoximine results in increased expression of GDF15 mRNA
Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of GDF15 mRNA]

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

GDP dissociation inhibitor 2

decreases expression

Buthionine Sulfoximine results in decreased expression of GDI2 mRNA

NCBI chr17:66,649,616...66,676,299
Ensembl chr17:66,649,619...66,676,366

G

glial fibrillary acidic protein

multiple interactions

(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

glutaredoxin

multiple interactions

Buthionine Sulfoximine inhibits the reaction [arsenite results in increased expression of GLRX protein]

NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680

G

glia maturation factor, beta

increases response to substance

GMFB protein results in increased susceptibility to Buthionine Sulfoximine

NCBI chr15:20,069,923...20,081,005
Ensembl chr15:20,067,263...20,080,331

G

glucose-6-phosphate isomerase

increases expression

Buthionine Sulfoximine results in increased expression of GPI1 mRNA

NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086

G

glutamic--pyruvic transaminase

multiple interactions

[allyl sulfide co-treated with dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate] inhibits the reaction [[Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein]; [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of GPT protein; [Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased expression of and results in increased activity of GPT protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of GPT protein]; Ursodeoxycholic Acid inhibits the reaction [[Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein]
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of GPT protein; [Methimazole co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of GPT protein; Buthionine Sulfoximine promotes the reaction [[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein]; Tranylcypromine inhibits the reaction [[Methimazole co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein]

PMID:15950962 PMID:26177832 PMID:27421576 PMID:29679711 PMID:30853469 More...

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

affects activity
multiple interactions

Buthionine Sulfoximine affects the activity of GPX1 protein
Buthionine Sulfoximine promotes the reaction [Microcystins analog results in increased expression of GPX1 mRNA]
Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of GPX1 mRNA]

PMID:15707499 PMID:24964298 PMID:25341683

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 2

increases expression

Buthionine Sulfoximine results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutathione peroxidase 3

increases expression

Buthionine Sulfoximine results in increased expression of GPX3 mRNA

NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035

G

glutathione peroxidase 4

multiple interactions

Buthionine Sulfoximine promotes the reaction [Acrolein results in decreased expression of GPX4 mRNA]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

growth factor receptor bound protein 2

decreases expression

Buthionine Sulfoximine results in decreased expression of GRB2 mRNA

NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309

G

gelsolin

increases expression

Buthionine Sulfoximine results in increased expression of GSN mRNA

NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402

G

glutathione-disulfide reductase

multiple interactions

Buthionine Sulfoximine inhibits the reaction [schizandrin B results in increased activity of GSR protein]; Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]]
Buthionine Sulfoximine inhibits the reaction [arsenite results in increased activity of GSR protein]
[Buthionine Sulfoximine co-treated with Carmustine] results in decreased activity of GSR protein; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of GSR protein; [cyanoginosin LR co-treated with Buthionine Sulfoximine] results in increased activity of GSR protein; Buthionine Sulfoximine inhibits the reaction [Microcystins analog results in decreased expression of GSR mRNA]; Buthionine Sulfoximine inhibits the reaction [schizandrin B results in increased activity of GSR protein]; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide results in increased expression of GSR mRNA]

PMID:12967637 PMID:16288907 PMID:17119269 PMID:21772021 PMID:24634002 More...

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione synthetase

decreases activity
increases expression

Buthionine Sulfoximine results in decreased activity of GSS protein
Buthionine Sulfoximine results in increased expression of GSS mRNA

PMID:10904027 PMID:10978506

NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198

G

glutathione S-transferase alpha 1

multiple interactions

Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of GSTA1 mRNA]

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase mu 1

increases expression

Buthionine Sulfoximine results in increased expression of GSTM1 mRNA

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase mu 2

increases expression

Buthionine Sulfoximine results in increased expression of GSTM2 mRNA

NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961

G

glutathione S-transferase pi 1

multiple interactions

Buthionine Sulfoximine inhibits the reaction [GSTP1 results in decreased susceptibility to Benzo(a)pyrene]
Buthionine Sulfoximine inhibits the reaction [Microcystins analog results in increased expression of GSTP1 mRNA]

PMID:19330882 PMID:24964298

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

hydroxyacyl-CoA dehydrogenase

increases expression

Buthionine Sulfoximine results in increased expression of HADH mRNA

NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353

G

HBS1-like translational GTPase

decreases expression

Buthionine Sulfoximine results in decreased expression of HBS1L mRNA

NCBI chr 1:16,092,529...16,170,082
Ensembl chr 1:16,092,547...16,170,074

G

heparin binding growth factor

increases expression

Buthionine Sulfoximine results in increased expression of HDGF mRNA

NCBI chr 2:173,370,147...173,379,756
Ensembl chr 2:173,370,465...173,379,747

G

hepatocyte growth factor

increases expression

Buthionine Sulfoximine results in increased expression of HGF protein

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

hypoxia inducible factor 1 subunit alpha

multiple interactions
increases activity

Buthionine Sulfoximine promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of HIF1A protein]
Buthionine Sulfoximine results in increased activity of HIF1A protein

PMID:11641398 PMID:11841787 PMID:17658243

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

high mobility group box 1

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of HMGB1 protein
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased secretion of HMGB1 protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased secretion of HMGB1 protein]

PMID:23986454 PMID:26177832

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

high mobility group box 2

increases expression

Buthionine Sulfoximine results in increased expression of HMGB2 mRNA

NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140

G

heme oxygenase 1

multiple interactions
increases expression

1-aminobenzotriazole inhibits the reaction [[Acetaminophen co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 1-aminobenzotriazole inhibits the reaction [[Butylated Hydroxyanisole co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 1-aminobenzotriazole inhibits the reaction [[Diclofenac co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 1-aminobenzotriazole inhibits the reaction [[Ticlopidine co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA]; [2-tert-butylhydroquinone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; [Buthionine Sulfoximine co-treated with Ascorbic Acid] promotes the reaction [Copper Sulfate results in increased expression of HMOX1 mRNA]; [Buthionine Sulfoximine co-treated with Dehydroascorbic Acid] promotes the reaction [cupric oxide results in increased expression of HMOX1 mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA; [monocrystalline iron oxide nanoparticle co-treated with Buthionine Sulfoximine co-treated with Dehydroascorbic Acid] results in increased expression of HMOX1 mRNA; [monocrystalline iron oxide nanoparticle co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; Buthionine Sulfoximine promotes the reaction [3-O-caffeoyl-1-methylquinic acid results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Acetaminophen results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Butylated Hydroxyanisole results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]; Buthionine Sulfoximine promotes the reaction [Copper Sulfate results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [cupric oxide results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Diclofenac results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Potassium Dichromate results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Raloxifene Hydrochloride results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Ticlopidine results in increased expression of HMOX1 mRNA]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA]
Buthionine Sulfoximine results in increased expression of HMOX1 protein
Buthionine Sulfoximine results in increased expression of HMOX1 mRNA; Buthionine Sulfoximine results in increased expression of HMOX1 protein
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of HMOX1 mRNA; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]
[6-formylindolo(3,2-b)carbazole co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; [Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of HMOX1 mRNA; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [[Cadmium Chloride co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [[chromium trioxide co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [[sodium arsenite co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [chromium trioxide results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Diclofenac results in increased expression of HMOX1 protein]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of HMOX1 mRNA]; Diclofenac promotes the reaction [Buthionine Sulfoximine results in increased expression of HMOX1 protein]

PMID:7626009 PMID:9152014 PMID:11841787 PMID:12763371 PMID:16274885 More...

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heme oxygenase 2

affects response to substance

HMOX2 affects the susceptibility to Buthionine Sulfoximine

NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148

G

heterogeneous nuclear ribonucleoprotein M

increases expression

Buthionine Sulfoximine results in increased expression of HNRNPM protein

NCBI chr 7:14,438,703...14,476,781
Ensembl chr 7:14,438,688...14,476,762

G

heat shock protein 90 alpha family class A member 1

increases expression

Buthionine Sulfoximine results in increased expression of HSP90AA1 protein

NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein 90 alpha family class B member 1

increases expression

Buthionine Sulfoximine results in increased expression of HSP90AB1 mRNA

NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488

G

heat shock protein family A (Hsp70) member 4

increases expression

Buthionine Sulfoximine results in increased expression of HSPA4 protein

NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001

G

heat shock protein family A (Hsp70) member 5

multiple interactions

Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of HSPA5 protein]

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

increases expression

Buthionine Sulfoximine results in increased expression of HSPA8 mRNA

PMID:7626009 PMID:15707499

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

intercellular adhesion molecule 1

multiple interactions
increases expression

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Buthionine Sulfoximine results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine inhibits the reaction [cinnamaldehyde inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Tetradecanoylphorbol Acetate promotes the reaction [Buthionine Sulfoximine results in increased expression of ICAM1 protein]
[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of ICAM1 mRNA

PMID:11164475 PMID:20116392 PMID:20351055 PMID:29154782

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

insulin-like growth factor binding protein 1

multiple interactions

Buthionine Sulfoximine inhibits the reaction [INS1 protein results in decreased expression of IGFBP1 mRNA]

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

interleukin 10

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]; Buthionine Sulfoximine promotes the reaction [methyldithiocarbamate promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL10 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL10 mRNA]

PMID:19339665 PMID:26177832

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 12B

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B protein]; Buthionine Sulfoximine inhibits the reaction [methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]]

PMID:12688424 PMID:19339665

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 17A

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of IL17A protein

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 1 alpha

multiple interactions

[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of IL1A mRNA; LY6G protein affects the reaction [[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of IL1A mRNA]

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
increases secretion

[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL1B mRNA; Acetylcysteine inhibits the reaction [[Buthionine Sulfoximine co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of IL1B protein]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL1B mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of IL1B protein; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Buthionine Sulfoximine promotes the reaction [hydroxyethyl methacrylate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; Buthionine Sulfoximine promotes the reaction [Tobacco Smoke Pollution results in increased secretion of and results in increased expression of IL1B protein]

PMID:11970852 PMID:12433058 PMID:23986454 PMID:26149495 PMID:26177832 More...

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 23 subunit alpha

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL23A mRNA

NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923

G

interleukin 4

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of IL4 protein; Buthionine Sulfoximine promotes the reaction [Methimazole results in increased expression of IL4 protein]

PMID:22407903 PMID:27421576

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

increases secretion
multiple interactions

Buthionine Sulfoximine results in increased secretion of IL6 protein
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Buthionine Sulfoximine inhibits the reaction [manganese chloride promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; Buthionine Sulfoximine inhibits the reaction [methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL6 mRNA; Acetylcysteine inhibits the reaction [[Buthionine Sulfoximine co-treated with Lipopolysaccharides] results in increased secretion of IL6 protein]; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of IL6 protein]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL6 mRNA]

PMID:11970852 PMID:12433058 PMID:15601679 PMID:19339665 PMID:23986454 More...

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

Buthionine Sulfoximine inhibits the reaction [INS1 protein results in decreased expression of IGFBP1 mRNA]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

Janus kinase 1

increases expression

Buthionine Sulfoximine results in increased expression of JAK1 mRNA

NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926

G

Janus kinase 2

decreases expression

Buthionine Sulfoximine results in decreased expression of JAK2 mRNA

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression
decreases activity

Buthionine Sulfoximine inhibits the reaction [Sodium Selenite results in increased expression of JUN mRNA]; Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of JUN mRNA]; Buthionine Sulfoximine promotes the reaction [Trioxsalen analog results in decreased activity of JUN protein]; Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of JUN mRNA]
Buthionine Sulfoximine inhibits the reaction [Cadmium Chloride results in increased expression of JUN mRNA]
Buthionine Sulfoximine results in decreased activity of JUN protein

PMID:7626009 PMID:7743507 PMID:11341981 PMID:11841787 PMID:11849044 More...

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of JUNB mRNA]

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

potassium voltage-gated channel subfamily A member 4

multiple interactions

[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCNA4 protein

NCBI chr 3:93,756,399...93,778,004
Ensembl chr 3:93,756,446...93,769,162

G

potassium voltage-gated channel subfamily D member 2

multiple interactions

[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 mRNA; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 protein

NCBI chr 4:49,775,812...50,277,746
Ensembl chr 4:49,776,246...50,277,728

G

Kelch-like ECH-associated protein 1

multiple interactions

Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Acrolein]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in increased abundance of Glutathione]

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

KLF transcription factor 4

multiple interactions

Buthionine Sulfoximine inhibits the reaction [KLF4 results in decreased susceptibility to Cisplatin]

NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602

G

KLF transcription factor 6

multiple interactions

Buthionine Sulfoximine promotes the reaction [[CYP2E1 protein co-treated with Vitamin K 3] results in increased expression of KLF6 protein]

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

karyopherin subunit beta 1

increases expression

Buthionine Sulfoximine results in increased expression of KPNB1 protein

NCBI chr10:82,145,662...82,174,437
Ensembl chr10:82,145,420...82,174,605

G

lipocalin 2

increases expression
multiple interactions

Buthionine Sulfoximine results in increased expression of LCN2 mRNA
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of LCN2 mRNA; [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of LCN2 mRNA; [zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of LCN2 mRNA; LY6G protein affects the reaction [[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of LCN2 mRNA]
Diclofenac promotes the reaction [Buthionine Sulfoximine results in increased expression of LCN2 mRNA]

PMID:23939143 PMID:29154782 PMID:29679711 PMID:30853469

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

lymphoid enhancer binding factor 1

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of LEF1 protein

NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794

G

leucine-rich pentatricopeptide repeat containing

increases expression

Buthionine Sulfoximine results in increased expression of LRPPRC protein

NCBI chr 6:9,859,816...9,942,294
Ensembl chr 6:9,859,867...9,942,293

G

microtubule-associated protein 1 light chain 3 beta

increases expression
multiple interactions

Buthionine Sulfoximine results in increased expression of MAP1LC3B protein; Buthionine Sulfoximine results in increased expression of MAP1LC3B protein modified form
Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of MAP1LC3B protein]; Cadmium Chloride promotes the reaction [Buthionine Sulfoximine results in increased expression of MAP1LC3B protein]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

mitogen activated protein kinase 1

multiple interactions

[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK1 protein; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine promotes the reaction [chromium hexavalent ion results in increased activity of MAPK1 protein]; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK1 protein]
[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased phosphorylation of MAPK1 protein; [ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK1 protein; Buthionine Sulfoximine promotes the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK1 protein; Cadmium Chloride promotes the reaction [Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK1 protein]

PMID:8616849 PMID:17191120 PMID:21971136 PMID:24401988 PMID:26177832 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen-activated protein kinase 11

decreases expression
multiple interactions

Buthionine Sulfoximine results in decreased expression of MAPK11 mRNA
Sodium Selenite inhibits the reaction [Buthionine Sulfoximine results in decreased expression of MAPK11 mRNA]

NCBI chr 7:120,218,471...120,225,488
Ensembl chr 7:120,218,478...120,225,395

G

mitogen activated protein kinase 14

increases phosphorylation

Buthionine Sulfoximine results in increased phosphorylation of MAPK14 protein

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions

[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK3 protein; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine promotes the reaction [chromium hexavalent ion results in increased activity of MAPK3 protein]; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK3 protein]
[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased phosphorylation of MAPK3 protein; [ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK3 protein; Buthionine Sulfoximine promotes the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK3 protein; Cadmium Chloride promotes the reaction [Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK3 protein]

PMID:8616849 PMID:17191120 PMID:21971136 PMID:24401988 PMID:26177832 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

[antimony trioxide co-treated with Buthionine Sulfoximine] results in decreased expression of MAPK8 protein; Buthionine Sulfoximine promotes the reaction [antimony trioxide results in increased activity of MAPK8 protein]; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide results in increased activity of MAPK8 protein]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased phosphorylation of MAPK8 protein]

PMID:14701702 PMID:16112521 PMID:36343453

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

decreases phosphorylation

Buthionine Sulfoximine results in decreased phosphorylation of MAPK9 protein

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

microtubule-associated protein tau

multiple interactions

(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

methionyl-tRNA synthetase 1

increases expression

Buthionine Sulfoximine results in increased expression of MARS1 protein

NCBI chr 7:63,121,142...63,138,550
Ensembl chr 7:63,121,142...63,138,495

G

myoglobin

multiple interactions

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased secretion of MB protein

NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383

G

myocyte enhancer factor 2a

increases expression

Buthionine Sulfoximine results in increased expression of MEF2A mRNA

NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948

G

O-6-methylguanine-DNA methyltransferase

multiple interactions
decreases activity

Buthionine Sulfoximine inhibits the reaction [MGMT protein results in increased susceptibility to Mitomycin]
Buthionine Sulfoximine results in decreased activity of MGMT protein

PMID:16039682 PMID:16950796

NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756

G

microRNA 101-2

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR101B mRNA

NCBI chr 1:226,860,371...226,860,467
Ensembl chr 1:226,860,371...226,860,467

G

microRNA 106b

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR106B mRNA

NCBI chr12:17,043,344...17,043,425
Ensembl chr12:17,043,344...17,043,425

G

microRNA 127

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR127 mRNA

NCBI chr 6:128,546,215...128,546,311
Ensembl chr 6:128,546,215...128,546,311

G

microRNA 133b

multiple interactions

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR133B mRNA; [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR133B mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of MIR133B mRNA

PMID:28263783 PMID:29679711 PMID:30853469

NCBI chr 9:23,098,134...23,098,217
Ensembl chr 9:23,098,134...23,098,217

G

microRNA 136

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR136 mRNA

NCBI chr 6:128,549,096...128,549,177
Ensembl chr 6:128,549,096...128,549,177

G

microRNA 137

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR137 mRNA

NCBI chr 2:206,480,881...206,480,982
Ensembl chr 2:206,480,884...206,480,985

G

microRNA 138-1

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR138-1 mRNA

NCBI chr 8:122,300,966...122,301,064
Ensembl chr 8:122,300,966...122,301,064

G

microRNA 141

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR141 mRNA

NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332

G

microRNA 148b

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR148B mRNA

NCBI chr 7:134,421,398...134,421,494
Ensembl chr 7:134,421,398...134,421,494

G

microRNA 151

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR151 mRNA

NCBI chr 7:105,172,377...105,172,473

G

microRNA 184

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR184 mRNA

NCBI chr 8:90,343,134...90,343,210
Ensembl chr 8:90,343,134...90,343,210

G

microRNA 187

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR187 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR187 mRNA

NCBI chr18:15,731,194...15,731,297
Ensembl chr18:15,731,194...15,731,297

G

microRNA 188

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR188 mRNA

NCBI chr X:15,247,715...15,247,794
Ensembl chr X:15,247,715...15,247,794

G

microRNA 190

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR190A mRNA

NCBI chr 8:67,850,987...67,851,071
Ensembl chr 8:67,850,987...67,851,071

G

microRNA 19a

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR19A mRNA

NCBI chr15:92,180,912...92,180,993
Ensembl chr15:92,180,912...92,180,993

G

microRNA 200a

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR200A mRNA

NCBI chr 5:166,648,494...166,648,582

G

microRNA 206

multiple interactions

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR206 mRNA; [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR206 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of MIR206 mRNA

PMID:28263783 PMID:29679711 PMID:30853469

NCBI chr 9:23,094,249...23,094,332
Ensembl chr 9:23,094,249...23,094,332

G

microRNA 20b

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR20B mRNA

NCBI chr X:132,422,211...132,422,282
Ensembl chr X:132,422,211...132,422,282

G

microRNA 210

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR210 mRNA

NCBI chr 1:196,326,343...196,326,452
Ensembl chr 1:196,326,337...196,326,454

G

microRNA 211

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR211 mRNA

NCBI chr 1:117,777,539...117,777,644
Ensembl chr 1:117,777,539...117,777,644

G

microRNA 224

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR224 mRNA

NCBI chr X:150,065,088...150,065,169
Ensembl chr X:150,065,088...150,065,169

G

microRNA 29b-1

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR29B-1 mRNA

NCBI chr 4:59,650,987...59,651,067
Ensembl chr 4:59,650,986...59,651,067

G

microRNA 322

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR322 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR322 mRNA

NCBI chr X:132,806,594...132,806,688
Ensembl chr X:132,806,594...132,806,688

G

microRNA 324

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR324 mRNA

NCBI chr10:54,734,680...54,734,762
Ensembl chr10:54,734,678...54,734,766

G

microRNA 328

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR328 mRNA

NCBI chr19:33,184,766...33,184,849
Ensembl chr19:33,184,766...33,184,849

G

microRNA 337

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR337 mRNA

NCBI chr 6:128,538,903...128,538,999
Ensembl chr 6:128,538,902...128,538,998

G

microRNA 339

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR339 mRNA

NCBI chr12:15,277,546...15,277,641
Ensembl chr12:15,277,546...15,277,641

G

microRNA 34b

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR34B mRNA

NCBI chr 8:51,410,244...51,410,327
Ensembl chr 8:51,410,244...51,410,327

G

microRNA 361

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR361 mRNA

NCBI chr X:78,246,206...78,246,275
Ensembl chr X:78,246,206...78,246,275

G

microRNA 375

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR375 mRNA

NCBI chr 9:76,457,911...76,457,985
Ensembl chr 9:76,457,911...76,457,985

G

microRNA 410

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR410 mRNA

NCBI chr 6:128,758,358...128,758,433
Ensembl chr 6:128,758,354...128,758,434

G

microRNA 449a

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR449A mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR449A mRNA

NCBI chr 2:44,670,714...44,670,804
Ensembl chr 2:44,670,714...44,670,804

G

microRNA 450a-1

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR450A1 mRNA

NCBI chr X:132,801,380...132,801,470
Ensembl chr X:132,801,380...132,801,470

G

microRNA 455

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR455 mRNA

NCBI chr 5:76,689,313...76,689,390
Ensembl chr 5:76,689,313...76,689,390

G

microRNA 671

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR671 mRNA

NCBI chr 4:10,580,747...10,580,827
Ensembl chr 4:10,580,738...10,580,835

G

microRNA 99a

multiple interactions

[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR99A mRNA

NCBI chr11:16,200,443...16,200,523
Ensembl chr11:16,200,443...16,200,523

G

matrix metallopeptidase 1

multiple interactions

[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA]

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

myeloperoxidase

multiple interactions

[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of MPO protein

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

mitochondrial ribosomal protein S7

increases expression

Buthionine Sulfoximine results in increased expression of MRPS7 mRNA

NCBI chr10:100,843,691...100,846,838
Ensembl chr10:100,843,356...100,847,129

G

metallothionein 1

increases expression
increases activity
multiple interactions

Buthionine Sulfoximine results in increased expression of MT1A mRNA
Buthionine Sulfoximine results in increased activity of MT1 promoter
Buthionine Sulfoximine promotes the reaction [Copper results in increased activity of MT1 promoter]; Buthionine Sulfoximine promotes the reaction [Paraquat results in increased expression of MT1 mRNA]; Dactinomycin inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Paraquat results in increased expression of MT1 mRNA]]
Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of MT1A mRNA]

PMID:7626009 PMID:8966720 PMID:9152014 PMID:14576086

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049

G

metallothionein 2A

multiple interactions

[Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of MT2 mRNA

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

metal-regulatory transcription factor 1

multiple interactions
decreases response to substance

MTF1 results in decreased susceptibility to [Buthionine Sulfoximine co-treated with cadmium sulfate]
MTF1 results in decreased susceptibility to Buthionine Sulfoximine

NCBI chr 5:137,062,319...137,107,136
Ensembl chr 5:137,062,376...137,107,136

G

5-methyltetrahydrofolate-homocysteine methyltransferase

multiple interactions

Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Buthionine Sulfoximine inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form]; Glutathione inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]]; mecobalamin inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]]

NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822

G

asparaginyl-tRNA synthetase 1

increases expression

Buthionine Sulfoximine results in increased expression of NARS1 protein

NCBI chr18:57,989,308...58,005,584
Ensembl chr18:57,989,308...58,005,622

G

necdin, MAGE family member

increases expression

Buthionine Sulfoximine results in increased expression of NDN mRNA

NCBI chr 1:115,849,168...115,850,767
Ensembl chr 1:115,849,105...115,850,767

G

NADH:ubiquinone oxidoreductase subunit A13

increases expression

Buthionine Sulfoximine results in increased expression of NDUFA13 mRNA

NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726

G

NFE2 like bZIP transcription factor 2

multiple interactions
affects expression
increases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which affects the localization of NFE2L2 protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which affects the localization of NFE2L2 protein; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Acrolein]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in increased abundance of Glutathione]; Buthionine Sulfoximine promotes the reaction [1,2-dihydroxynaphthalene analog results in increased activity of NFE2L2 protein]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased expression of NFE2L2 protein]; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased phosphorylation of NFE2L2 protein]
Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of and affects the localization of NFE2L2 protein]; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of NFE2L2 mRNA]; Buthionine Sulfoximine promotes the reaction [arsenic trioxide results in increased expression of and affects the localization of NFE2L2 protein]
Buthionine Sulfoximine affects the expression of NFE2L2 protein
Buthionine Sulfoximine results in increased expression of NFE2L2 mRNA
[6-formylindolo(3,2-b)carbazole co-treated with Buthionine Sulfoximine] results in increased expression of NFE2L2 mRNA; Buthionine Sulfoximine affects the localization of and results in increased activity of NFE2L2 protein; Buthionine Sulfoximine affects the reaction [[NFE2L2 affects the susceptibility to sulforaphane] which affects the susceptibility to Acrolein]; Buthionine Sulfoximine affects the reaction [[NFE2L2 affects the susceptibility to sulforaphane] which affects the susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [Dextromethorphan results in increased activity of NFE2L2 protein]; Buthionine Sulfoximine inhibits the reaction [Hypochlorous Acid results in increased expression of NFE2L2 mRNA]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to Acrolein]]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to Chlorambucil]]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to cumene hydroperoxide]]

PMID:17980396 PMID:18785192 PMID:19303893 PMID:19608619 PMID:20932822 More...

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions

Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of NFKB1 protein]; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased activity of [NFKB1 protein binds to RELA protein]]

PMID:11970852 PMID:12433058

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions
increases expression

Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]
NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of NFKBIA mRNA]

PMID:11970852 PMID:12433058 PMID:23472850

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nerve growth factor

multiple interactions
affects response to substance
increases expression

Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of NGF mRNA]; NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of NFKBIA mRNA]; NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of TXN1 mRNA]; NGF protein affects the reaction [Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein]
NGF protein affects the susceptibility to Buthionine Sulfoximine

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

NLR family, pyrin domain containing 3

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of NLRP3 mRNA
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of NLRP3 mRNA

PMID:23986454 PMID:26177832

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nitric oxide synthase 2

multiple interactions
increases expression

[Carmustine co-treated with Buthionine Sulfoximine] inhibits the reaction [TNF protein results in increased expression of NOS2 protein]; Buthionine Sulfoximine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]; Buthionine Sulfoximine promotes the reaction [Carmustine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]]; Buthionine Sulfoximine promotes the reaction [Potassium Cyanide results in increased expression of NOS2 protein]; Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Buthionine Sulfoximine]
Buthionine Sulfoximine results in increased expression of NOS2 mRNA
[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA; Acetylcysteine inhibits the reaction [[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA]
Buthionine Sulfoximine promotes the reaction [Trioxsalen analog results in decreased expression of NOS2 mRNA]

PMID:7532384 PMID:9826428 PMID:16259964 PMID:16933320 PMID:23939143

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NPC intracellular cholesterol transporter 1

decreases expression

Buthionine Sulfoximine results in decreased expression of NPC1 mRNA

NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049

G

NAD(P)H quinone dehydrogenase 1

increases activity
increases expression
multiple interactions

Buthionine Sulfoximine results in increased activity of NQO1 protein
Buthionine Sulfoximine results in increased expression of NQO1 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which res